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ABSTRACT 
Phosphatidylcholine (PC) is an essential compound for cell membranes, VLDL, cell 
signaling, and bile. PC can be synthesized directly from choline by the CDP-choline 
pathway or it can be synthesized via the methylation of phosphatidylethanolamine (PE) by 
phosphatidylethanolamine N-methyltransferase (PEMT). The latter of the two pathways 
requires methyl groups from three S-adenosylmethionines (SAM) and is responsible for 
~30% of the hepatic PC production. Other methyltransferases, including betaine- 
homocysteine S-methyltransferase (BHMT) and glycine N-methyltransferase (GNMT), have 
been shown to have increased activity with diabetes. Furthermore, GNMT has increased 
activity with all-trans-retinoic acid (ATRA) supplementation. This thesis explores the 
affects of diabetes and ATRA supplementation on phospholipid methylation by PEMT. I 
found a 2-fold increase in PEMT activity with diabetes alone and in combination with ATRA 
supplementation. ATRA administration alone had no affect on PEMT activity. PEMT 
activity has been proposed to be an important regulator of homocysteine levels. However, 
we found a 30-35%decrease in homocysteine levels in diabetes when PEMT activity was 
elevated. There were decreased plasma total homocysteine concentrations with ATRA 
administration, which had no affect on PEMT activity. There was also a significant decrease 
in PE and an increase in PC as a percentage of total phospholipids in the diabetic and ATRA 
supplemented groups. I hypothesized the increased PEMT activity was the result of 
increased betaine usage by BHMT in diabetes, leading to an effective choline deficiency. 
Upon supplementation with choline or betaine in the diabetic state, there was no change in 
PEMT activity. These data suggest PEMT activity may be altered by hormonal changes in 
the diabetic state, rather than by a lack of choline or betaine. 
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CHAPTER 1. GENERAL INTRODUCTION 
Thesis Organization 
The first chapter of this thesis includes the organization of the thesis and a short 
description of the overall research questions addressed. Chapter 2 is a review of the relevant 
literature on methyl group metabolism, importance of homocysteine, phospholipid synthesis, 
and some potential modulators of these systems. Chapters 3 and 4 each focus on research 
conducted by the author. Chapter 5 provides general conclusions for the thesis. The 
Appendix presents research done by the author for a study conducted by Kristin Nieman. 
Chapters 3 and 4 and the appendix each contain an introduction, materials and methods, 
results, and discussion. Following the appendix is the comprehensive Literature Cited for all 
sections of this thesis. 
Description of the Research Questions 
Methyl groups from S-adenosylmethionine (SAM) can be transferred to a variety of 
compounds in the body including proteins, nucleic acids, and lipids. DNA methylation is 
required to maintain proper gene expression, while phospholipid methylation helps maintain 
cell membranes, cell signaling, and bile and VLDL secretion. A lack of methyl groups can 
lead to a variety of diseases including cancer, birth defects, and fatty liver (1-4). 
Furthermore, a lack of methyl groups can lead to elevated concentrations of homocysteine in 
the body, which is an independent risk factor for cardiovascular disease (4) and has been 
linked to a number of other diseases including Alzheimer's and osteoporosis (5). 
Previously, my research group has shown Type 1 diabetes and administration of 
retinoids alters hepatic methyl group metabolism, both alone and in combination (6). In 
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some cases administration of retinoids was able to attenuate the effects of diabetes on methyl 
group metabolism. 
Phosphatidylcholine (PC) synthesis via methylation by phosphatidylethanolamine N- 
methyltransferase (PEMT) is responsible for ~30% of the PC produced by the liver (7-9). 
This reaction requires the use of three methyl groups from SAM and consequently produces 
three S-adenosylhomocysteines (SAHs). The potentially high usage of methyl groups by 
PEMT has led many researchers to believe PEMT is an important regulator of homocysteine 
concentrations in the body (10). Therefore, it is important to determine how factors that 
affect methyl group metabolism and plasma homocysteine levels, e.g., diabetes and retinoid 
administration, affect phospholipid methylation. Furthermore, if PEMT activity is affected, 
what consequences does this altered activity have on liver lipid and phospholipid 
concentrations. This thesis examines how phospholipid methylation is affected by diabetes 
and retinoids, what consequences altered phospholipid methylation has, and explores nutrient 
supplementation to correct changes in phospholipid methylation. 
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CHAPTER 2. LITERATURE REVIEW 
Methyl Group Donors 
Choline 
Approximately 30 mmoles of methyl groups/d are consumed as choline in the diet, 
and it is estimated over 60% of the free choline in the liver is converted to betaine (11). The 
dietary reference intake (DRI), established by the Food and Nutrition Board of the Institute 
of Medicine 1997-2001, for choline is 425 mg/d and 550 mg/d for adult women and men, 
respectively. The upper intake limit for adults is 3.5 g/d. Plants and animals alike have the 
ability to synthesize choline. Choline is consumed as free choline or lecithin. Liver, eggs, 
soybeans, and peanuts (12, 13) are good sources of lecithin, which is the major form of 
choline consumed in the human diet (14). Choline concentrations in blood and tissues are 
directly proportional to the amount of choline consumed in the diet (15). Much of the 
choline consumed in the diet is rapidly "trapped" by the liver, but some is removed by the 
kidney, oxidized to betaine, and excreted (14). The liver and the kidney are important in 
maintaining choline concentrations in the plasma. Choline is an important dietary 
component because it is the precursor for sphingomyelin, phosphatidylcholine (PC), 
acetylcholine, platelet-activating factor (PAF), and betaine (16) (Figure 2.1). 
Choline Supplementation 
Choline is used in the treatment of several diseases. Choline is converted to 
acetylcholine by choline acetyltransferase (14). Systemic administration of pharmacological 
doses of choline rapidly increases the concentration of choline in the brain (17, 18). 
Increased choline concentrations, in turn, leads to increased acetylcholine concentrations in 
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Figure 2.1. Structure of choline and selected metabolites (modified from Zeisel and 
Blusztajn, 1994) 
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the brain, peripheral cholinergic neurons, and tissues. Pharmacological doses of choline have 
been used to treat tardive dyskinesia (19), a movement disorder, and improve memory (20), 
which may have implications in treating Alzheimer's disease (21). 
choline supplementation also has been used in the treatment of hypertension (14). 
choline administration may lower blood pressure through the cholinergic vagus nerve, 
through the vasodilator effects of choline, or a combination of both (22). Another possibility 
is increased synthesis of PAF, which has the ability to lower blood pressure (16). 
Additionally, choline has been shown to affect plasma lipids, but with conflicting 
results. Oral choline supplementation increased plasma cholesterol, phospholipid, HDL, and 
LDL concentrations (23, 24). However, there have been studies showing a lowering of blood 
cholesterol with choline supplementation (16). With such inconsistent results, choline 
administration is not the optimal choice for treatment of hypercholesterolemia. 
choline deficiency 
choline deficiency, though rare in humans, has been studied extensively in animals. 
A choline-deficient diet can rapidly, within hours or days in rats, cause an accumulation of 
lipids in the liver, particularly triacylglycerols (TAGs) (25, 26). This may be due to a 
decreased ability to assemble lipoproteins in order to transport TAGs out of the liver. This 
view is further supported by the fact that choline deficiency also decreases blood VLDL 
concentrations. Because of the intimate involvement of phosphatidylcholine in the synthesis 
and secretion of lipoproteins, a decrease in liver phosphatidylcholine could alter these 
processes. 
Fatty liver is not the only health consequence of choline deficiency. A choline-
deficient diet causes kidney lesions in weanling rats (25). Also, choline deficiency causes 
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irreversible hypertension in rats (27). Furthermore, choline-deficiency is the only known 
nutrient deficiency that can cause spontaneous hepatocarcinomas in the absence of a 
carcinogen (16). Additionally, choline deficient rats are more sensitive to cancer causing 
agents. 
Betaine 
Betaine has a chemical formula of (CH3)3N+CH2COO- and a molecular weight of 
117.2 g/mol (1). Average dietary betaine intakes range from 1 g/d to as much as 2.5 g/d. 
However, there have been studies that supplemented up to 20 g/d of betaine for one year and 
that dosage was well tolerated (28). Betaine is found in many foods including wheat, 
shellfish, spinach, and sugar beets. Betaine accumulates in plants as a result of drought, high 
salinity, or temperature stress. In addition to obtaining betaine directly from the diet, choline 
can also serve as a source of betaine. choline can be oxidized to betaine aldehyde by the 
enzyme choline dehydrogenase in mitochondria and betaine aldehyde is oxidized to betaine 
by betaine aldehyde dehydrogenase in mitochondria and cytosol. Betaine donates one 
methyl group to homocysteine to form methionine and dimethylglycine using the enzyme 
betaine-homocysteine S-methyltransferase (BHMT). Dimethylglcyine donates another 
methyl group to tetrahydrofolate to form sarcosine and 5,10-methylenetetrahydrofolate in a 
reaction catalyzed by dimethylglycine dehydrogenase (29). Sarcosine is further 
demethylated by sarcosine dehydrogenase to form glycine and 5,10-
methylenetetrahydrofolate. In all, betaine can donate three methyl groups to the one carbon 
pool, either directly or via re-methylation of tetrahydrofolate. 
In patients with homocystinuria, which is marked by elevated plasma homocysteine 
concentrations, oral betaine supplementation was able to effectively decrease plasma total 
homocysteine (29). Oral betaine supplementation decreases plasma total homocysteine in 
healthy human subjects in adose-dependent manner (30). Studies have shown dietary 
supplementation of choline in rats increases hepatic betaine concentrations regardless of the 
amount of methionine in the diet (29). This increase in liver betaine concentrations is 
accompanied by an increase in BHMT concentrations (31). 
Other than donating methyl groups, betaine also plays a role as an organic osmolyte 
(29). Cells maintain their hydration state by altering concentrations of intracellular inorganic 
ions, such as sodium and potassium, and organic osmolytes, such as betaine (1). Inorganic 
ions can only accumulate to a certain level due to their effects on protein structure and 
function. Betaine, however, has very little interaction with protein surfaces, and so betaine 
can accumulate to high levels in the cell to maintain osmolarity without affecting normal cell 
function. 
Folate 
Folate is a general term that actually describes many compounds derived from 
tetrahydrofolate (THF) (32). Dietary folate contributes approximately 5-10 mmoles methyl 
groups/d (3). Folate, in the form of 5-methyltetrahydrofolate (5-CH3-THF), donates one 
methyl group to homocysteine to form methionine and THF. This reaction is catalyzed by 
methionine synthase (MS), a B12 dependent enzyme. THE can be converted to 5,10- 
methylenetetrahydrofolate (5,10-CH2-THF), which can then be converted to 5-CH3-THF by 
5,10-methylenetetrahyrofolate reductase (MTHFR). In 1998, the Food and Drug 
Administration (FDA) required that all enriched grain products be fortified with folate. 
Folate fortification led to a decreased prevalence of folate-deficient related diseases (33). In 
particular, the incidence of the neural tube defect spina bifida has decreased by 20% in the 
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United States (2). 
Methionine 
Methionine is asulfur-containing essential amino acid. Methionine is converted to 
the active form, S-adenosylmethionine (SAM), by the enzyme methionine 
adenosyltransferase. Methionine is one of the primary sources of methyl groups in human 
foods, with a consumption of approximately 10 mmol methyl groups/d (3). Homocysteine 
can be converted to methionine using methyl groups from betaine or 5-CH3-THF (34). 
Deficiency of methionine leads to a decrease in the SAM:SAH ratio (35). Pyridoxine (B6) 
deficiency leads to similar results, probably because it is a cofactor for cystathionine (3- 
synthase (CBS). Pyridoxine deficiency inhibits the activity of CBS, leading to decreased 
catabolism of homocysteine by the transsulfuration pathway. Decreased catabolism of 
homocysteine can result in a "build up" of homocysteine, which is in equilibrium with S- 
adenosylhomocysteine (SAH), and it is the increased SAH concentrations that inhibit 
methyltransferase activity. 
Methyl Group Metabolism 
Methyl group metabolism involves the activation of methionine being converted to its 
active form SAM, which then donates cone-carbon group to various biomolecules including 
proteins, nucleic acids, and phospholipids (Figure 2.2). This reaction leaves SAH which is 
then hydrolyzed to homocysteine. Homocysteine can be re-methylated to methionine, it can 
be converted to cysteine, or it can be secreted from the cell. Betaine and 5-CH3-THF are the 
methyl group donors for re-methylation of homocysteine. Regulation of this pathway is 
important to maintaining the normal cell cycle. In the following sections, each part of this 
pathway will be discussed in detail. 
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Figure 2.2. Methyl group metabolism pathway 
BHMT = Betaine-homocysteine S-methyltransferase; CBS =Cystathlonlne ~i-synthase; 
DMG = Dimethylglycine; 5-CH3-THF = 5-Methyltetrahydrofolate; 5,10-CH2-THF = 5,10-
Methylenetetrahydrofolate; SAM = S-adenosylmethionine; SAH = S-adenosylhomocysteine; 
THF = Tetrahydrofolate; XMT =methyltransferase 
Transmethylation 
Methyltransferases (shown as XMT in Figure 2.2) catalyze the removal of a methyl 
group from SAM to form SAH. In this reaction, the methyl group from SAM is donated to a 
variety of molecules including protein, lipids, and nucleic acids. Most methyltransferases are 
located predominantly in the liver, pancreas, and kidney. There are many methyltransferases 
in animals, but this review will focus on the three primary users of SAM in the liver, glycine 
N-methyltransferase (GNMT), guanidinoacetate N-methyltransferase (GAMY), and 
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phosphatidylethanolamine N-methyltransferase (PEMT). 
Glycine N-methyltransferase 
Glycine N-methyltransferase is located in the liver, pancreas, and kidney and 
comprises 0.9-3% of all the hepatic cytosolic protein (36). This enzyme is responsible for 
~20% of the SAM-dependent one carbon reactions in rabbit liver, but this value varies 
among species (36). GNMT catalyzes the addition of a methyl group from SAM to gycine 
to create sarcosine. Unlike many other methyltransferases, GNMT is not as sensitive to 
feedback inhibition by SAH. GNMT is allosterically inhibited by S-CH3-THF, an 
intermediate in the folate metabolic pathway (37, 38). The inhibition of GNMT activity is a 
key component that enables GNMT to optimize the SAM to SAH ratio in the cell, thereby 
increasing the effectiveness of other methyltransferases. 
Guanidinoacetate N-methyltransferase 
Guanidinoacetate is produced by the kidney and travels to the liver via the blood. 
There, it is converted to creatine by the enzyme GAMT, which converts one SAM to SAH in 
the process. GAMT is expressed predominantly in the liver and pancreas, with expression in 
other tissues being too low for detection (39). In healthy humans, this reaction produces ~l 
g/d of creatine, but can be decreased by creatine supplementation (40). Reduced creatine 
synthesis is due to the feedback inhibition of creatine on GAMT. Therefore, endogenous 
creatine production returns to normal levels upon termination of supplementation (41). 
GAMT deb ciency is an autosomal recessive genetic disorder that results in under production 
of creatine (39). This lack of creatine biosynthesis leads to epilepsy, muscular hypotonia, 
and mental retardation. 
According to Mudd et al. (42), GAMT uses approximately 75% of the hepatic one-
11 
carbon pool, making it the largest consumer of SAM in the liver. However, Jacobs et al. (43) 
recently presented evidence that phosphatidylethanolamine N-methyltransferase (PEMT) 
may consume more SAM than GAMT. This finding is important because the 
methyltransferase that consumes the most SAM can have a large impact on other 
methyltransferase reactions and homocysteine concentrations. In a study published by Stead 
et al. (44), rats were fed a diet supplemented with guanidinoacetate or creatine for two 
weeks. Plasma total homocysteine was increased by 50% in rats supplemented with 
guanidinoacetate whereas plasma total homocysteine was decreased by 25% in rats 
supplemented with creatine. The results of the study by Stead et al. further elucidate the role 
of GAMT activity in regulating plasma homocysteine levels. 
Phosphatidylethanolamine N-methyltransferase 
As the primary focus of this research is on PEMT, this enzyme will be discussed in 
depth in a later section. 
Re-methylation 
Re-methylation of homocysteine to methionine conserves the one-carbon skeleton 
(45). Re-methylation can be achieved by one of two enzymes, betaine-homocysteine S- 
methyltransferase or methionine synthase. Methionine levels often depend on the ability of 
these two enzymes to function properly. 
Betaine-homocysteine S-methyltransferase 
Betaine-homocysteine S-methyltransferase is one of two enzymes capable of re- 
methylating homocysteine to methionine. BHMT is a folate-independent enzyme that 
catalyzes the conversion of betaine to dimethylglycine (DMG) by donating a methyl group 
from betaine to homocysteine to form methionine. The activity of BHMT is elevated when 
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betaine is supplemented in the diet. BHMT is predominately located in the liver; however, in 
some species, such as humans and pigs, there is appreciable BHMT activity in the kidney 
(46). 
Methionine synthase 
Methionine synthase (MS) is a folate-dependent enzyme with a cobalamin (B 12) 
cofactor. MS is responsible for the re-methylation of homocysteine to methionine using 5- 
CH3-THF as a methyl donor. Unlike other enzymes involved in methyl group metabolism, 
MS is ubiquitously expressed in most tissues (46). MTHFR is responsible for irreversibly 
converting 5,10-CH2-THF to 5-CH3-THF and is also universally expressed in most tissues. 
Because MTHFR is unidirectional under physiological conditions, if there is a cobalamin 
deficiency and 5-CH3-THF can not be converted to THF, then there is a "build-up" of 5-CH3-
THF. MTHFR is sensitive to allosteric regulation and is inhibited by elevated levels of 
SAM. 
Transsulfuration 
Transsulfuration is vital to regulation of homocysteine levels. The enzymes of the 
transsulfuration pathway, cystathionine R-synthase (CBS) and cystathionine y-lyase 
(cystathionase), are predominately located in the liver, pancreas, and kidney. These enzymes 
are especially important in the kidney. In a study by House et al. (46), they found ~SO% of 
plasma homocysteine was removed by the kidney in rats, with little to no urinary excretion of 
homocysteine. Furthermore, they found there was little re-methylation of homocysteine to 
methionine in the kidney; so the ability of the kidney to regulate plasma homocysteine 
concentrations was primarily a result of the transsulfuration pathway. 
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Cystathionine (3-synthase 
Cystathionine (3-synthase is the first enzyme in the transsulfuration pathway of 
homocysteine. CBS irreversibly condenses homocysteine and serine to form cystathionine. 
CBS has a pyridoxine requirement for activity. There are polymorphisms of CBS that inhibit 
the activity of the transsulfuration pathtyay, but about half of the subjects are responsive to 
supplementation with large doses of pyridoxine (47). Inborn errors of CBS can lead to 
homocystinuria (48). CBS can be activated by elevated levels of SAM and SAH (46). 
Cystathionine y-lyase 
Cystathionine y-lyase (cystathionase) is the next enzyme in the transsulfuration 
pathway, and it also has pyridoxine as a cofactor. Cystathionase converts cystathionine to 
cysteine, a-ketobutyrate, and NH4+ (46). The cysteine can be used for glutathione synthesis, 
an important compound in redox reactions. Cysteine can also be used for protein synthesis, 
or it can be further catabolized. 
Homocysteine 
Biochemistry of homocysteine 
Homocysteine is asulfur-containing amino acid and is present in the body in the L- 
homocysteine form (49). Most of the homocysteine present in the body is from catabolism of 
methionine, with very little intake from the diet (50). S-adenosylhomocysteine is converted 
to homocysteine in a reversible reaction catalyzed by S-adenosylhomocysteine hydrolase. 
This enzyme is present in a wide variety of tissues with the most activity in pancreas, liver, 
and kidney tissues. The equilibrium of this reaction favors SAH; however, in vivo 
homocysteine is rapidly converted to methionine or cystathionine to ensure that the reaction 
favors the formation of homocysteine (49). 
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Homocysteine exists in the plasma as ~30% free and ~70% protein-bound, mostly to 
albumin (50). Homocysteine binds albumin through the formation of disulfide bonds with 
cysteine residues. Less homocysteine is protein-bound in the cytosol of tissues, with 
anywhere from 5-40% being protein-bound in various tissues of the rat (51). There is little 
known about homocysteine concentrations in human tissues, so it is not known if plasma 
concentrations reflect tissue concentrations (50). 
Diseases associated with homocysteine 
Homocystinuria is a disease in which homocysteine concentrations in plasma are 
severely elevated causing urinary excretion of homocysteine (48). The first case was 
reported in 1962, followed by rapid reporting of more cases. Homocystinuria is a result of 
inborn errors of CBS or MS. Complications of homocystinuria include dislocation of the 
ocular lens, skeletal abnormalities, mental retardation, and vascular disease. Treatments for 
homocystinuria have focused on lowering plasma homocysteine concentrations. As 
mentioned previously, about half of the subjects with CBS deficiency are able to lower their 
plasma homocysteine concentrations with pyridoxine supplementation. Treatments for those 
who are unresponsive to pyridoxine supplementation or have a defect in MS include a low 
methionine diet and betaine supplementation. Lowering of plasma total homocysteine in 
these subjects reduces their risk for cardiovascular disease. 
The complications of homocystinuria led researchers to study the impacts of mildly 
elevated plasma total homocysteine concentrations, or hyperhomocysteinemia. 
Hyperhomocysteinemia is characterized by plasma total homocysteine concentrations greater 
than 15 µM, with normal levels ranging from 5-15 µM (46). Hyperhomocysteinemia is 
considered an independent risk factor for cardiovascular disease (4, 52) and atherosclerosis 
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(53). It is not necessary to have extremely high levels of homocysteine to be at increased 
risk. There is a 60% and 80% increased risk of coronary heart disease in women and men, 
respectively, with just a 5µM increment in total homocysteine (54). 
The reduction in neural tube defects with folate supplementation indicated that 
elevated homocysteine concentrations may play a role in their development. Birth defects 
are the leading cause of infant mortality, causing 22% of all infant deaths (2). Seven percent 
of these deaths are caused by neural tube defects. A study by Rosenquist et al. (55) found 
that treating chick embryos with homocysteine caused neural tube defects and ventricular 
septal defects despite normal levels of folate. Other pregnancy complications believed to be 
associated with hyperhomocysteinemia include spontaneous abortion and early-onset 
preeclampsia (56). 
Finally, patients with Alzheimer's disease commonly have elevated levels of 
homocysteine and low circulating levels of folate and cobalamin (57). These observations 
seem to be consistent with the fact that subjects with homocystinuria commonly experience 
mental retardation. Taken together, these findings could mean that folate supplementation 
could prevent or delay the onset of Alzheimer's disease, which is significant because at this 
time there is no cure for Alzheimer's disease. 
It is important to remember that most of the studies showing elevated homocysteine 
levels to be associated with certain diseases are epidemiological studies and therefore can not 
show a cause and effect relationship. Homocysteine may just be one sign of other disorders 
that are actually causing the disease. This means that it may not be enough to lower 
homocysteine levels to prevent disease; it may be necessary to treat the underlying cause of 
the elevated homocysteine levels to prevent disease. More research needs to be done to 
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elucidate the relationship between hyperhomocysteinemia and health complications. 
Phosphatidylcholine 
Synthesis 
CDP-choline pathway 
Phosphatidylcholine (PC) can be synthesized by the CDP-choline pathway, also 
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Figure 2.3. Phosphatidylcholine synthesis via CDP-choline pathway (modified from Vance 
and Walkey, 1998) 
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known as the Kennedy pathway (Figure 2.3). It is estimated that 70% of hepatic PC is 
synthesized by the CDP-choline pathway (58). Choline is converted to phospllocholine by 
choline kinase using ATP as a phosphate donor. Phosphocholine is then combined with 
cytidine triphosphate (CTP) to form CDP-choline by CTP:phosphocholine 
cytidylyltransferase (CT}. This is the rate-limiting step in the CDP-choline pathway. CDP- 
choline is then combined with diacylglycerol (DAG) catalyzed by phosphatidylcholine 
glyceride transferase to form PC. The CDP-choline pathway mainly synthesizes medium 
chain and saturated PC (7). 
PC can be catabolized to phosphatidic acid (PtdOH) and choline by phospholipase D 
(PLD) (Figure 2.4) (59). In this manner, the PC pool can serve as a store of choline. 
Furthermore, synthesis of PC by the methylation pathway can be considered de novo 
synthesis of choline. The phosphatidic acid (PtdOH) produced by this enzyme can be broken 
down further by phospholipase A~ (PLAN) to lysophosphatidic acid, which is used in ce11 
signaling as described later. 
PC 
PLD 
PtdOH 
PLA~ 
Choline 
LPA 
Figure 2.4. Catabolism of PC to choline 
PEMT pathway 
An alternative pathway for PC production in the liver is via methylation of 
phosphatidylethanolamine (PE) by phosphatidylethanolarnine N-methyltransferase (PEMT). 
PEMT is a methyltransferase that transfers methyl groups from three SAMs to PE to form 
three SAHs and one PC (Figure 2.5). The intermediates of this reaction are 
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phosphatidylmonomethylethanolamine (PMME) and phosphatidyldimethylethanolamine 
(PDME). 
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Figure 2.5. Methylation of phosphatidylethanolamine to phosphatidylcholine (modified 
from Vance and Walkey, 1998) 
PEMT is a 22.5-kDa protein that is mainly associated with the endoplasmic 
reticulum, but a second form of PEMT can be found on the mitochondria-associated 
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membrane (60). The two forms are encoded by the same gene and deletion of this gene 
removes all hepatic PEMT activity. PEMT is considered a liver specific enzyme, but there 
have been trace amounts found in other tissues (Table 2.1). PEMT is very active in the 
myelinating fetal brain, with activity becoming almost nonexistent after birth (61). 
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Table 2.1. Distribution of PEMT activity among various tissues (modified from Vance and 
Ridgeway, 1988) 
Conversely, PEMT is not significantly expressed in the liver until one day before birth (62). 
However, PEMT expression can be decreased by partial hepatectomy (63). PEMT activity 
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decreased by 50% within 24 hr of partial hepatectomy, with activity returning to normal by 
the time liver reached adult size. Additionally, when lead nitrate was used to stimulate liver 
growth, there was a decrease in PEMT activity (64). This evidence suggests that PEMT is 
less active in rapidly dividing liver cells. This idea led researchers to investigate the role of 
PEMT in liver cell growth. PEMT activity is practically undetectable in hepatocarcinoma 
cell lines and transfection of PEMT into hepatocarcinoma cells such as McArdle RH-7777 
cells results in overexpression of PEMT and inhibition of cell growth (65). The authors 
believe PEMT is involved in signaling for differentiation and apoptosis. 
The PEMT pathway accounts for approximately 30% of the PC production in the 
liver (7-9). In contrast, PC synthesis by the PEMT pathway is not necessary for survival, as 
Pemt ~ knock out mice can live long lives when maintained with acholine-sufficient diet 
(66). However, when Pemt ~ knock out mice are fed a diet deficient in choline, they die 
within a few days. Times of choline deficiency may be one reason for the conservation of 
PEMT throughout evolution. PEMT synthesizes mostly long chain and highly unsaturated 
PC species (18 : l / 18 :1; 18:0/ 18 :2; 18 :2/20 :4; 18 : l /20:4; 18:0/20:4; 18:0/22:6; 18 :1 /22:5) as 
opposed to the CDP-choline pathway, which mostly forms medium chain and saturated PC 
species (16:0/ 18 :1; 18:0/ 18 :2; 18 :1 / 18 :1) (7) . PC synthesized by the two pathways may be 
utilized in different ways in the cell, such as PC from PEMT being targeted to VLDL 
synthesis (67). Differences in length and saturation of PC formed by the two pathways gives 
another possible reason why PEMT is physiologically significant. 
It was previously thought that PEMT consumed approximately 15% of the SAM 
pool, whereas GAMT, another methyltransferase, used about 75% of the pool (42). As 
mentioned previously, this belief has been recently questioned in a paper by Jacobs et al. (43) 
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that indicated PEMT consumed 2-3 times more SAM than GAMT and would therefore be a 
greater contributor to SAH production. These findings are logical, as PEMT consumes three 
SAMs to make one PC, while GAMT only consumes one SAM to make creatine. If PEMT 
is a maj or producer of homocysteine, then PEMT may also play an important role in the 
regulation of homocysteine. In CTa-deficient mice hepatocytes, there is an 80% increase in 
PC synthesis via PE methylation and a 40% increase homocysteine secretion (43). 
Additionally, Pemt-~ knockout mice have 50% lower plasma homocysteine concentrations 
and hepatocytes isolated from these mice secrete 50% less homocysteine (10). Furthermore, 
cell lines stably expressing various levels of ER- and MAM-localized PEMT showed 
increased homocysteine secretion with increased PEMT activity (68). 
PEMT activity has been shown to be regulated by a number of things including 
substrate, product, and hormones. Similar to other methyltransferases mentioned earlier in 
the review, the concentration of SAH seems to play a role in regulation of PEMT activity 
because SAH has a higher affinity for the binding site of PEMT than for SAM (60, 69). In a 
study by Hoffman et al. (70), a decrease in the SAM:SAH was responsible for drastically 
reducing the activity of PEMT. Similarly, rats fed a diet deficient in pyridoxine, which is a 
necessary cofactor for catabolism of homocysteine by the transsulfuration pathway, had 
significantly less PC synthesized by the methylation pathway as compared with controls (35). 
The authors believed an increase in SAH was responsible for the decreased PEMT activity. 
PE concentrations also seem to be important regulators of PEMT activity, but PC has yet to 
be shown to affect PEMT activity (60). 
Availability of choline in the diet can also affect PEMT activity. Rats fed a choline-
deficient diet experience a 63 % increase in PEMT activity within two days (71), but they do 
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not experience an increased expression of PEMT until they are on a choline deficient diet for 
more than three weeks (58). 
Castano et al. (72) showed incubation of rat hepatocytes with glucagon increased the 
activity of PEMT. Incubation of rat hepatocytes with cAMP or NaF, an activator of 
adenylate cyclase, had similar effects as glucagon. Additionally, incubation with a 
phosphodiesterase inhibitor, which decreases intracellular cAMP, significantly decreased the 
activity of PEMT. This inhibition is strong evidence that PEMT activity can be hormonally 
regulated, possibly via changes in the phosphorylation state of the enzyme or induction of 
gene expression. 
Coordination of the two pathways 
There is mounting evidence that PC synthesis via the CDP-pathway and the PEMT 
pathway is coordinated. When 3-deazaadenosine was injected into rats, it increased the 
concentration of SAH in the liver, which effectively inhibited the activity of hepatic PEMT 
(73). There was a concurrent increase in PC synthesis by the CDP-choline pathway. 
Hepatocytes isolated from CTa-deficient mice have CT activity that is only 15% of control 
values, with only a 10-20% decrease in hepatic PC levels, suggesting increased PC synthesis 
via PE methylation (43). Similarly, when McArdle RH-7777 rat hepatoma cells, which lack 
PEMT expression, are transfected with cDNA for PEMT2, there is markedly decreased 
expression of CT in the hepatocytes (74). When PEMT activity is decreased in rapidly 
dividing cells, CT activity is elevated, providing further evidence for the coordination of the 
two pathways (60). 
While it seems very likely that there is cross-talk between these two pathways, the 
mechanism for this is still unknown. As mentioned previously, there is evidence that cAMP 
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analogues increase PEMT activity (72, 75), presumably by a phosphorylation mechanism. 
There is also evidence that cAMP analogues can inhibit CT activity via phosphorylation by 
cAMP-dependent protein kinases (76). This relationship shows that the two pathways can be 
regulated in opposite directions by the same signal, presumably glucagon. This may be one 
mechanism to coordinate PC synthesis by the two pathways; however, this is probably not 
the only mechanism because it does not clearly explain the changes in PEMT and CT activity 
in rapidly dividing cells. 
Function 
Very low density lipoproteins 
Very low density lipoproteins (VLDL) consist of apoB, triacylglycerol, cholesterol, 
cholesterol esters, and phospholipids and are made in the liver. Of the phospholipids, 
approximately 60% are PC and are located only on the surface (77). Full-sized VLDL 
particles are assembled on the endoplasmic reticulum, whereas nascent VLDL particles can 
be synthesized on the endoplasmic reticulum or the Golgi lumina (77). It has been shown 
that PC synthesized by PEMT is required for VLDL assembly (67). 
Bile secretion 
Lipids make up 23-29% of the total solids in bile, and approximately 80% of this is 
PC (78). Large quantities of PC are secreted into the bile every day. For example a 20 g 
mouse has ~20 mg of hepatic PC and secretes ~23 mg/d into the bile (59). 
Phosphatidylcholine and bile salts form a complex with cholesterol to solubilize the 
cholesterol. The concentrations of PC and bile salts determine how much cholesterol can be 
solubilized. Phosphatidylcholine alone can solubilize cholesterol, but at a much lower ratio 
than in combination with bile salts. Humans require multiple drug-resistant protein 3 
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(MDR3), a PC-specific flippase, in order to secrete PC into bile (59). Mice similarly require 
MDR2 for the secretion of PC into bile, and lack of this protein completely inhibits biliary 
PC secretion. When MDR2 knock-out mice (Mdr2-~) were bred with PEMT knock-out mice 
(Pemt ~) and fed a choline-deficient diet, they were able to adapt to a new low level of 
choline homeostasis and survive for at least 90 d (59). In comparison, Pemt ~ mice fed a 
choline-deficient diet who continued to secrete PC into bile died within 4-5 d. Furthermore, 
heterozygous MDR2 knock-out mice (Mdr2+~) secrete 40% less PC than do wild-type mice 
and have significantly less PEMT activity (79). This decreased activity is probably due to a 
decreased need for PC synthesis. These mice are less likely to develop non-alcoholic 
steatohepatitis (NASH) than wild-type mice fed a choline- and methionine-deficient diet, an 
animal model used to study NASH. 
Cell signaling 
Phosphatidylcholine accounts for ~50% of the membrane phospholipids (80). When 
a receptor in the plasma membrane is activated, it can subsequently activate a GTP-binding 
protein (G protein). Activation of a G protein is the first step in cell signaling and leads to 
activation of phospholipase C. Most forms of phospholipase C hydrolyze 
phosphatidylinositol bisphosphate to generate 1,2-sn-diacylglycerol, however, there are PC- 
specific phospholipase Cs (80). One of the products of PC hydrolysis is 1,3-sn-
diacylglycerol, which maintains the signaling cascade generated by 1,2-sn-diacylglycerol. 
There are additional products from phosphatidylcholine hydrolysis that act as second 
messengers including phosphatidic acid, lysophosphatidylcholine, and free fatty acids such as 
arachidonic acid. 
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Besides acting as a second messenger, diacylglycerol can also be used to activate 
protein kinase C (PKC) by binding and causing a conformational change (80). This 
conformational change effectively "opens" up the catalytic site and activates the enzyme. 
PKC enhances substrates downstream to further amplify the signal that originally generated 
the diacylglycerol. 
Choline deficiency leads to hepatocellular carcinomas in rats after 12 mo on a 
choline-deficient diet (81). There were alterations in 1,2-sn-diacylglycerol concentrations 
and PKC activity in these rats, which are important in intracellular signaling for cell growth, 
that may have led to the increase in carcinogenesis. There may also be an increased 
sensitivity to carcinogens due to increased DNA synthesis from the increased cell death and 
regeneration seen in choline deficiency. It was previously believed that choline deficiency 
caused increased apoptosis in hepatocytes due to an accumulation of lipids and decreased 
plasma membrane integrity, but evidence has shown apoptosis is induced before this occurs 
(80). It is now thought choline deficiency induces apoptosis through free radicals because 
inhibitors of free radical formation inhibit hepatocyte apoptosis during choline deficiency. 
Factors that Affect Methyl Group Metabolism 
Diabetes 
General information 
According to the American Diabetes Association (ADA), there are approximately 
20.8 million people in the United States living with diabetes. The two major forms of 
diabetes are Type 1, or insulin-dependent, and Type 2, or non-insulin-dependent, diabetes 
mellitus. This review will focus primarily on Type 1 diabetes, as a Type 1 diabetic model 
was used to conduct the research presented later in this thesis. 
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Type 1 diabetes is an autoimmune disorder and is generally recognized as being a 
familial disorder. However, while genetics may play a strong role in the development of 
Type 1 diabetes, 90% of subjects with Type 1 diabetes do not have afirst-degree relative 
with diabetes (82). During the development of Type 1 diabetes, (3-cells, the insulin- 
producing cells of the pancreas, are destroyed with the preservation of a- and 8-cells of the 
pancreas. A viral infection may cause the (3-cell destruction through cytotoxicity or 
triggering autoimmunity to ~3-cells by infecting the (3-cells or lymphocytes. There are also 
other environmental factors that may influence the development of Type 1 diabetes, but these 
are not fully understood at this time. 
There are many complications associated with Type 1 diabetes. Whereas insulin 
treatment does prevent death from diabetes, it does not completely prevent complications due 
to diabetes (83). One of the most common disorders associated with Type 1 diabetes is 
retinopathy. Retinopathy is damage to or lesions of the retina and is the leading cause of 
blindness for people between 20 and 74 years old in the United States (84). The 
development of retinopathy may be associated with the presence of neuropathy, or damage to 
the nerves as a result of high glucose concentrations or ischemia due to microvascular 
changes (85). 
Nephropathy is another common complication of Type 1 diabetes. An increased 
urinary excretion of albumin marks the onset of nephropathy (85). Increased glomerular 
filtration rate (GFR) is associated with the early stages of nephropathy, with a rapid decline 
in GFR as end-stage renal failure progresses (85). Elevated blood lipids and homocysteine 
are highly correlated with renal failure. 
Hypertension and heart disease are serious complications of diabetes. The incidence 
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of hypertension in diabetics is twice that ofnon-diabetics (86). There are four main types of 
hypertension in diabetes-- renal hypertension, hypertension without nephropathy, systolic 
hypertension, and orthostatic hypertension. Each of these types has a different pathogenesis 
and treatment. In Type 1 diabetic subjects, almost all who develop nephropathy also develop 
hypertension. Development of hypertension in a diabetic subject can have a maj or impact on 
their risk for coronary artery disease (CAD) (87). 
As mentioned earlier, hyperhomocysteinemia is an independent risk factor for 
cardiovascular disease (4, 52). There is generally a decrease in plasma homocysteine levels 
in Type 1 diabetics with normal renal function. Plasma total homocysteine levels return to 
normal when insulin is given to Type 1 diabetic rats (46, 88). Unfortunately, renal failure is 
a common complication of diabetes and plasma homocysteine concentrations are highly 
correlated with kidney function; so, renal failure leads to hyperhomocysteinemia (89). 
Fatty liver and NASH are additional complications of diabetes (90-93). NASH is 
characterized by inflammation and accumulation of fat and fibrous tissue in the liver. 
Although NASH is not always associated with diabetes, as much as 75% of the people with 
NASH have diabetes. In many people this is a stable condition, but in some cases NASH can 
lead to cirrhosis. The causes of NASH are unknown, but many people with NASH have 
elevated blood cholesterol and triacylglycerol concentrations. Currently there is no cure for 
NASH; so, it is important to find the causes of it so that it potentially can be prevented. 
Effects on methyl group metabolism 
A paper by Nieman et al. (6), offers an extensive view of the early changes that occur 
in methyl group metabolism in uncontrolled Type 1 diabetes using a streptozotocin-mediated 
diabetic rat model. They found an increase in GNMT activity and abundance and a decrease 
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in MS activity. The combined increase in GNMT activity and decrease in MS activity would 
suggest an increase in plasma homocysteine, but instead there was a decrease in plasma 
homocysteine. This decrease was probably the result of an increase in BHMT activity and an 
increase in CBS abundance, which re-methylates homocysteine to methionine and converts 
homocysteine to cysteine, respectively. There were increased concentrations of SAM and 
SAH, but no change in their ratio. Plasma homocysteine is initially decreased in diabetes but 
is elevated as renal failure progresses. The initial reduction in plasma homocysteine is 
probably the result of the characteristic increase in glomerular filtration rate with the onset of 
diabetes (94). The increase in GNMT, BHMT, and CBS activities, the decrease in MS 
activity, and the decrease in plasma homocysteine all seem to hold true in a Type 2 diabetic 
rat model (95). The activities of CBS, cystathionase, and MS, as well as plasma total 
homocysteine concentrations, all return to normal in Type 1 diabetic rats treated with insulin 
(46, 88). 
The effect of diabetes on PEMT has not been consistent in past studies (61, 96-98). 
In the 1985 paper by Xue and Snoswell, they found PEMT activity to be reduced in alloxan-
diabetic sheep (98). However, while they did find an increase in GNMT activity, they also 
found decreased activity of BHMT, no change in MS activity, and no change in CBS activity. 
These results seen in the sheep model seem to be very different than those seen in the rat 
model. The decrease in PEMT activity in alloxan-diabetic rats is supported in papers by 
Cabrero et al. and Hoffman et al. (96, 99). However, an increase in PEMT activity was seen 
in the cardiac subcellular membrane and brain of diabetic rats and mice, respectively (61, 
97). 
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Retinoids 
General information 
Vitamin A is a term that describes a family of fat-soluble vitamins (100). The DRI 
(dietary reference intake) for vitamin A set by the Food and Nutrition Board of the Institute 
of Medicine is 700 µg/d and 770 µg/d for adult women and men, respectively, and a tolerable 
upper intake level of 3,000 µg/d for both genders. The vitamin A family can be further 
differentiated into provitamin A carotenoids and retinoids, which includes retinol, retinal, and 
retinoic acid. Some naturally occurring retinoids as well as synthesized retinoids have been 
shown to have pharmacological uses. One such retinoid, all-trans-retinoic acid, has both 
biological and pharmaceutical properties. All-trans-retinoic acid is marketed as Tretinoin°
and Vesanoid~ and is used in the treatment of acne and acute promyelocytic leukemia (APL) 
(101). Retinoic acid is thought to have its effects by influencing gene expression. Retinoic 
acid can bind retinoic acid receptor (RAR) and retinoid X receptor (RXR), which are nuclear 
transcription factors (Figure 2.7) (100). RAR and RXR then bind RAR and RXR response 
elements (RARE and RXRE) in the promoter regions of genes to influence gene expression. 
The genes with RAR and RXR response elements often code for proteins that are 
regulators of cell development, proliferation, and differentiation. In the case of APL 
treatment, all-tYans-retinoic acid induces the differentiation of leukemic promyelocytes into 
mature cells so that they can be eventually degraded instead of continuing to divide (102). 
Some common side effects associated with using pharmacological doses of retinoic acid 
include retinoic acid syndrome, elevated concentrations of triacylglycerols in blood (103, 
104), depression/suicidal thoughts, and birth defects. Retinoic acid syndrome is 
characterized by fever, respiratory distress, hypotension, and renal failure (100). Retinoic 
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Figure 2.7. Schematic of how retinoic acid can influence gene expression 
RE = Retinyl Ester; R =Retinol; CRBP =Cellular Retinol Binding Protein; RA =Retinoic 
Acid; CRABP =Cellular Retinoic Acid Binding Protein; RAR =Retinoic Acid Receptor; 
RARE =RAR Response Element 
acid administration has also been associated with hepatic steatosis (103, 105, 106). Because 
of the severe side effects of retinoic acid administration, treatments can only be used for short 
periods of time and patients must be under constant medical supervision, including monthly 
check-ups when retinoic acid is used to treat acne. 
Effects on methyl group metabolism 
Aside from the other side effects of retinoic acid administrations, it has also been 
shown to disrupt methyl group metabolism (6, 107-113). Daily oral doses of retinoic acid 
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increased the activity, abundance, and mRNA of GNMT and lowered plasma homocysteine 
levels (6, 108-112). Additionally, MS activity was increased by administration of all-trans- 
retinoic acid (6). Fell and Steele showed that 1000 IU/g diet of retinol led to a decreased 
synthesis of PC by the PEMT pathway, which led to a decrease in hepatic PC levels as a 
percentage of total phospholipids (107). 13-Cis-retinoic acid, another form of retinoic acid, 
was shown to increase hepatic SAM levels, which led to a significant increase in the SAM to 
SAH ratio (6, 113). Conversely, in the study by Nieman et al. (6) there was no change in the 
SAM to SAH ratio when rats were dosed with all-tans-retinoic acid. Finally, yet another 
paper reported a significant decrease in hepatic SAM levels in rats fed 1000 IU/g of diet of 
retinol (6, 107). These findings suggest the effects of retinoids on methyl group metabolism 
may be linked to the form of vitamin A that is used in the study. 
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CHAPTER 3. STREPTOZOTOCIN-DIABETIC RATS HAVE 
INCREASED ACTIVITY OF HEPATIC 
PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE' 
A paper to be submitted to Diabetes 
Cara S Hartz2'3 and Kevin L SchalinskeZ°4
Abstract 
Diabetes and all-trans-retinoic acid (ATRA) have been shown to induce the 
expression of the folate-independent enzyme betaine-homocysteine S-methyltransferase 
(BHMT) and stimulate the activity of the folate-dependent enzyme methionine synthase, 
respectively, with a concurrent decrease in homocysteine concentrations. 
Phosphatidylcholine (PC) is an essential phospholipid that can be synthesized by two 
different pathways-- the CDP-choline pathway and the S-adenosylmethionine (SAM)- 
dependent methylation of phosphatidylethanolamine (PE) by phosphatidylethanolamine N- 
methyltransferase (PEMT). Recent studies have suggested that PEMT is a significant 
consumer of methyl groups from SAM and is major determinant of homocysteine pools. 
Thus, we investigated how diabetes and ATRA, both individually and together, affect SAM- 
dependent phospholipid methylation. Rats received a single injection of streptozotocin (60 
mg/kg body weight) or vehicle followed by administration of ATRA (30 µmol/kg body 
weight) or vehicle for 5 d. The hepatic activity of PEMT was increased 50% in both diabetic 
rat groups, whereas administration of ATRA was without effect. The proportion of PC (% 
total phospholipids) was increased in all treatment groups, resulting in a decrease in the PE to 
PC ratio. The upregulation of phospholipid methylation in diabetic rats would be expected to 
increase homocysteine pools; however, total plasma homocysteine was decreased 30-35% in 
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all treatment groups as compared with the control group. Thus, under diabetic conditions 
alterations in the activity of PEMT was not directly correlated to changes in homocysteine 
concentrations. The increase in PEMT, as well as BHMT, taken together with the elevated 
biliary secretion of PC, may indicate an increased requirement for choline in the diabetic 
state. 
Introduction 
Phosphatidylcholine (PC)5 is an important phospholipid component of cell 
membranes, hepatic lipoproteins, and bile and is often used in cell signaling pathways (114). 
Impaired PC biosynthesis can lead to an accumulation of triacylglycerols in the liver (115) 
and decreased secretion of VLDL (116), resulting in hepatosteatosis. PC can be synthesized 
by two different pathways. The cytidine 5'-diphosphate (CDP)-choline pathway involves 
three different enzymes: choline kinase, CTP:phosphocholine cytidylyltransferase (CT), and 
choline-phosphate transferase and is present in all nucleated cells (7, 117). The second 
pathway, primarily present in the liver, is the phosphatidylethanolamine N-methyltransferase 
(PEMT) pathway. The PEMT pathway converts phosphatidylethanolamine (PE) to PC by 
using S-adenosylmethionine (SAM) as a methyl donor with S-adenosylhomocysteine (SAH) 
as a by-product and accounts for 20-40% of normal hepatic PC synthesis (9). 
Guanidinoacetate methyltransferase (GAMY), a hepatic enzyme that methylates 
guanidinoacetate to form creatine using SAM as the methyl donor, is the major consumer of 
methyl groups in the liver (42). It has been estimated that ~75% of the hepatic SAM pool is 
consumed by GAMY and ~15% by PEMT (42). However, in a recently published paper by 
Jacobs et al. (43), their findings suggest PEMT consumes 2-3 times more of the hepatic SAM 
pool than GAMY and would therefore produce more homocysteine. The contribution of 
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PEMT activity to homocysteine production is an important finding, because 
hyperhomocysteinemia has been shown to be associated with cardiovascular disease (4, 52) 
and atherosclerosis (53). Thus, it is important to understand PEMT function, not only for its 
capacity to synthesize PC, but also for its role in homocysteine regulation. 
Our laboratory has shown that diabetes and administration of pharmacological doses 
of all-trans-retinoic acid (ATRA) disrupts methyl group and homocysteine metabolism in the 
liver (6, 108, 109, 112). The activity of glycine N-methyltransferase (GNMT), a key protein 
in the regulation of hepatic methyl group metabolism, was significantly increased following 
administration of streptozotocin (STZ) or ATRA, individually or in combination (6). The 
induction of GNMT would be expected to decrease the methyl group pool and increase 
homocysteine concentrations; however, homocysteine concentrations were decreased in 
diabetes and ATRA supplementation because of an increase in the activities of the folate- 
independent enzyme betaine homocysteine S-methyltransferase (BHMT) and the folate- 
dependent enzyme methionine synthase (MS), respectively. Because ATRA administration 
and diabetes disrupts the metabolism of methyl groups and homocysteine, it is important to 
determine their effects, if any, on SAM-dependent phospholipid methylation. 
To date, studies directed at examining the relationship between diabetes and PEMT 
have met with conflicting results (61, 96-99). Hoffman et al. (99) and Cabrero et al. (96) 
reported that hepatic PEMT activity was decreased in alloxan-diabetic rats, which is similar 
to the decrease found in alloxan-diabetic sheep (98). For extrahepatic tissues, the activity of 
PEMT was increased in the cardiac subcellular membrane and brain of STZ-diabetic rats and 
mice, respectively (61, 97). Although PEMT activity was not determined, Wijekoon et al. 
(95) recently reported a decrease in hepatic PC concentrations in Zucker diabetic (Type 2) 
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fatty (ZDF) rats, whereas plasma PC concentrations were elevated. It is not known how a 
diabetic state results in alterations of phospholipid methylation, however, it may be the result 
of characteristic changes in hormone levels such as insulin and glucagon. For example, 
glucagon has been shown to increase PEMT activity in cultured hepatocytes (72, 75, 118). 
Therefore, it is important to determine how diabetes, alone and in combination with ATRA 
administration, affects phospholipid methylation and its potential influence on circulating 
levels of homocysteine. 
Materials and Methods 
Chemicals 
Reagents were obtained from the following: S-adenosyl-L-[methyl-3H]methionine, 
PerkinElmer Life and Analytical Sciences (Boston, MA); STZ, ATRA, and SAM, Sigma-
Aldrich (St. Louis, MO); and soy PE and soy PC standards, Avanti Polar Lipids, Inc. All 
other chemicals were analytical grade. 
Animals and diets 
All animal experiments were performed in compliance with the Iowa State University 
Laboratory Animal Resources Guidelines. For both studies, male Sprague-Dawley (Harlan 
Sprague-Dawley, Indianapolis, IN) rats (125-149 g) were housed in plastic cages with a 12-
hour light:dark cycle and given food and water ad libitum. The control diet has been 
previously described (113). For experimental study 1, 25 rats were randomly assigned to 
receive a single intraperitoneal injection of STZ (60 mg/kg body weight) on d 0 and 
sacrificed on d 3, 5, or 7. Non-diabetic control rats were injected with the vehicle (10 
mmol/L citrate buffer, pH 4.5) and sacrificed on d 0 and 7. For experimental study 2, 24 rats 
were randomly assigned to one of four treatment groups: control, STZ, ATRA, or both 
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treatments (STZ+ATRA). After diabetes initiation, ATRA was orally administered daily in 
corn oil at a dose of 30 µmol/kg body weight for 5 d. For both studies, rats were anesthetized 
with an intraperitoneal injection of ketamine:xylazine (90:10 mg/kg body weight) and blood 
samples were collected via cardiac puncture in heparinized syringes. Samples of whole 
blood were used to determine blood glucose using a commercial kit (Sigma-Aldrich, St. 
Louis, MO). Additional whole blood samples were centrifuged at 4,000 X g for 5 min and 
the plasma fraction was stored at -70°C until analysis. Livers were rapidly removed and a 
one-gram portion was used for preparation of microsomes; remaining liver samples were 
snap-frozen in liquid nitrogen and stored at -70°C. 
Isolation of liver microsomes 
Approximately 1 g of liver was homogenized with a Polytron-Aggregate apparatus 
(Brinkmann Instruments Inc., Westbury, NY) in 4 volumes of ice-cold 10 mmol/L Tris HCl 
(pH 7.4) containing 0.25 mol/L sucrose. The homogenate was centrifuged at 16,000 X g for 
20 min at 4°C followed by centrifugation of the supernatant (1-2 mL) at 105,000 X g for 60 
min at 4°C. The resulting supernatant was discarded and the pellet was resuspended in 400 
µL of 0.25 mol/L sucrose. The microsomal fraction was stored at -70°C until determination 
of PEMT activity. The protein concentration of the microsomal fraction was determined by 
the Bradford method (119) using a commercial kit (Coomassie Plus, Pierce). 
PEMT activity 
The enzymatic activity of PEMT was determined by measuring the incorporation of 
radiolabeled methyl groups from S-adenosyl-L-[methyl-3H]methionine into phospholipids by 
the method of Duce et al. (120) with modifications. In brief, the reaction mixture contained 
-, 
0.1 rnmol/L SAM, 2 µCi S-adenosyl-L-[methyl-'H]methionine, 10 mmol/L HEPES, 4 
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mmol/L dithiothreitol (DTT), 5 mmol/L MgC12, and 750 µg protein in a final volume of 550 
µL. Exogenous PE was not added to the reaction mixture because it has not been shown to 
significantly increase the reaction rate (121, 122). Following incubation in a 3 7°C water bath 
for 10 min, the reaction was terminated by pipetting 100 µL of the assay mixture into 2 mL 
chloroform:methanol:2 N HCl (6:3:1, v:v:v) in duplicate. The chloroform phase was washed 
three times with 1 mL 0.5 mol/L KCl in 50% methanol, transferred to a glass scintillation 
vial, and dried at room temperature. The dried lipid fraction was reconstituted in 5 mL 
Scintverse°  (Fisher Scientific, Pittsburgh, PA) and the radioactivity was determined by liquid 
scintillation counting. 
Plasma homocysteine 
Total homocysteine (free and protein-bound) concentrations were determined 
according to a previously described method (123). Briefly, 300 µL of plasma, 30 µL of 1 
mmol/L N-acetylcysteine, and 30 µL of 10% tributylphosphate in dimethylformamide were 
incubated at 4°C for 30 min. To terminate the reaction, 300 µL of 10% trichloroacetic acid 
and 1 mmol/L EDTA were added and samples were centrifuged at 1,000 X g for 5 min. For 
derivatization, a 100 µL sample of the supernatant was transferred to a tube containing 20 µL 
of 1.55 mol/L sodium hydroxide, 250 µL of borate buffer (0.125 mol/L, pH 9.5), and 100 µL 
of 4-fluoro-7-sulfobenzofurazan (1 g/L). Samples were incubated for 60 min at 60°C, 
filtered, and analyzed using HPLC with fluorometric detection. 
Lipid analysis 
Frozen liver samples were thawed and total liver lipids were extracted by the method 
of Folch et al. (124). A fraction of the Folch extract was dried and weighed to quantify total 
liver lipids. To determine specific phospholipid concentrations, total lipid extracts were 
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fractionated on a silica Sep-Pak cartridge (Waters, Milford, MA). Lipid extracts dissolved in 
chloroform:methanol (2:1) were loaded on the column and samples were sequentially eluted 
with 10 mL of chloroform for the neutral lipids, 15 mL of acetone:methanol (9:1) for the 
glycolipids and ceramides, and 15 mL of methanol for the phospholipids. The phospholipids 
in the methanol fraction were dried, reconstituted in 250 µL chloroform, and a 20 µL aliquot 
was injected onto a HPLC system for quantification of phosphatidylethanolamine, 
phosphatidylcholine, and total phospholipids using a Pholipidec Soy Lecithin Column 
(Astec, Whippany, NJ) by the method of Palacios and Wang with modifications (125). Soy 
PE and PC standards (Avanti Polar Lipids, Alabaster, AL) were used to quantify hepatic 
concentrations of PE and PC. Using plasma from whole blood samples and Folch lipid 
extracts of liver, triacylglycerols were analyzed using a commercial kit (Sigma-Aldrich, St. 
Louis, MO). 
Statistical analysis 
The mean values from each treatment group were compared using one-way ANOVA 
at a significance level of 5%. A one-way ANOVA on ranks was performed when the test for 
normality failed. If there was a significant difference among the means, comparisons were 
accomplished using Fisher's least significant difference procedure. Correlation coefficients 
were determined using Pearson Product Moment. All statistical analyses were performed 
using SigmaStat 3.1 (SPSS, Chicago, IL). 
Results 
Hepatic PEMT activity was rapidly increased by diabetes. Because insulin 
release after STZ injection may vary considerably, it was first important to determine the 
hepatic activity of PEMT as a function of time from the onset of diabetes. The activity of 
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PEMT increased over 7 d following the injection of STZ with the activity being significantly 
elevated 58% and 72% on d 5 and 7, respectively, as compared to control values (Figure 
3.1). 
ATRA administration was without affect on hepatic PEMT activity. The second 
study also demonstrated that diabetes increased PEMT activity, with or without ATRA 
administration. Both groups of diabetic rats (STZ and STZ+ATRA) exhibited significantly 
higher PEMT activity after 5 d as compared to control values (Figure 3.2); however, 
administration of ATRA alone or in combination with STZ had no effect on PEMT activity. 
Plasma homocysteine concentrations were reduced by both diabetes and ATRA. 
Plasma homocysteine levels were reduced 32% in the STZ group (11.3 ~ 0.8 µmol/L) as 
compared with the control group (16.7 ~ 1.6 µmol/L) (Figure 3.3). Similarly, plasma 
homocysteine concentrations were reduced ~35% in the ATRA (10.9 ~ 01.0 µmol/L) and the 
STZ+ATRA group (10.1 ~ 1.1 µmoUL). Therefore, no correlation was demonstrated 
between the activity of PEMT and circulating homocysteine concentrations (r = 0.109, P = 
0.611). 
Diabetes and ATRA administration increased the hepatic PE: PC ratio. There 
were no significant differences in total phospholipids among the four treatment groups (data 
not shown). Total hepatic PE concentrations and the percent PE of total phospholipids were 
reduced in the STZ and ATRA groups as compared to control values (Figure 3.4). The total 
hepatic PC concentrations were not significantly different among the treatment groups (data 
not shown); however, the percent PC of total phospholipids was increased in the STZ and 
ATRA groups. Collectively, these alterations in PE and PC concentrations reduced the ratio 
of PE: PC by 37% compared to control values. 
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Triacylglycerols accumulated in the liver with ATRA administration, which was 
modulated by the diabetic state. Liver TAG concentrations were increased ~ 150% in the 
ATRA group which consequently had higher liver lipid concentrations (Table 3.1). Whereas 
STZ alone had no effect on TAG concentrations, STZ in combination with ATRA resulted in 
a 400% increase in plasma TAG concentrations, with no difference in liver TAG 
concentrations as compared to the control group. These data suggest there may be an 
increased ability to secrete TAG from the liver in an acute diabetic state. 
Discussion 
Regulation of PEMT for the SAM-dependent synthesis of phosphatidylcholine is an 
important transmethylation reaction and represents a significant use of methyl groups. PC 
synthesis is required for cell membranes, bile secretion, and the ability to secrete VLDL from 
the liver. we have shown in these studies that the activity of PEMT is rapidly elevated in a 
type 1 diabetes model, resulting in a decrease in the PE:PC ratio. Taken together with our 
previous finding that BHMT activity is elevated under diabetic conditions (6), these current 
studies may reflect an increased requirement for PC production from the SAM-dependent 
pathway. These results also may indicate that diabetes is characterized by an increased use 
of choline for homocysteine re-methylation. It is not clear whether the increased production 
of PC is compensatory for the loss of choline for homocysteine re-methylation at the expense 
of CDP-dependent PC synthesis, or is the result of a specific increased requirement for PC 
synthesis in diabetic rats, such as increased biliary secretion (126). There is evidence that 
PEMT activity can be regulated by the need for PC synthesis. A study by Igolnikov and 
Green (79) showed decreased PEMT activity in Md~+~ mice as compared with wild-type 
mice. The Md~+~ mice secrete -V40% biliary PC than the wild-type mice and therefore have a 
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decreased need for PC synthesis. 
Liver triacylglycerolss accumulated with ATRA administration, similar to the results 
seen by Schalinske and Steele (106) with 13-cis-retinoic acid supplementation. However, in 
the diabetic group that received ATRA supplementation, plasma triacyglycerols were 
elevated, but not liver triacylglycerols. These data suggest there is an increased secretion of 
VLDL in the diabetic state and this is what prevented liver TAG accumulation due to ATR.A. 
PC is the predominant phospholipid in VLDL, so the increased VLDL secretion would 
require increased PC synthesis. 
In addition to phospholipid metabolism, these results have significant implications for 
the relationship between PEMT function and homocysteine homeostasis. Recent studies 
have shown that regulation of PEMT is tightly correlated to homocysteine production and 
bile synthesis. Using Pemt ~ knock out mice, it has been demonstrated that a lack of PEMT 
expression resulted in low circulating concentrations of homocysteine, whereas 
homocysteine secretion was enhanced following induction of PEMT expression in hepatoma 
cells (68, 127). Likewise, CTP:phosphocholine cytidylyltransferase-a knockout mice 
exhibited a 2-fold increase in PEMT activity, similar to our findings in diabetic rats, that 
resulted in an increase in homocysteine production and secretion (43). A recent paper further 
demonstrates that the lethality due to hepatic depletion of PC in PEMT knockout mice may 
be the result of biliary secretion and supplemental choline greatly enhances survival (59). 
Taken together with our findings, diabetes appears to be another factor that has a major 
impact on the regulation of PEMT and PC synthesis. This is supported by the observation 
that biliary PC secretion is elevated in diabetic rats (126). 
Of particular interest in our studies was the finding that, although PEMT activity was 
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elevated in diabetic rats, it did not correlate with changes in homocysteine concentrations in 
the plasma. All diabetic rats exhibited an elevation in hepatic PEMT activity and reduced 
homocysteine levels, presumably owing to the elevation in BHMT. Thus, in an acute 
diabetes model, the expected overproduction of homocysteine as a result of both PEMT and 
GNMT elevation appears to be compensated for by an increase in folate-independent 
homocysteine re-methylation. This may be due in part to provide methyl groups for SAM- 
dependent transmethylation reactions, such as the synthesis of PC. Others have shown that 
increased catabolism of homocysteine via transsulfuration is also a major factor contributing 
to the hypohomocysteinemia exhibited by diabetic rats (88, 128). 
It is not clear as to the signal underlying regulation of PEMT in a diabetic state, 
although it is most likely the result of changes in hormone concentrations and concomitant 
alterations in the supply of substrates for methyl group/ homocysteine metabolism. It has 
been shown that incubating hepatocytes with glucagon or cAMP increases PEMT activity, 
potentially the result of altering its phosphorylation state (75). Other factors that affect 
PEMT activity include B6 status (35) and the ratio of SAM/ SAH (129), although we did not 
find that methylation capacity was altered in diabetic rats (6). Because many of the findings 
reported for type 1 diabetes models have also been demonstrated in a type 2 model using 
ZDF rats (95), alterations in substrate or cofactor availability may be a more plausible 
explanation than the direct effects of hormonal imbalance. 
Our previous studies using diabetic and ATRA-treated rats demonstrated a clear 
interaction between these two treatments with respect to folate-dependent and folate- 
independent re-methylation of homocysteine, as well as its catabolism by the transsulfuration 
pathway (6). Moreover, the combination of diabetes or glucocorticoid treatment with ATRA 
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administration exerted an additive effect on inducing GNMT expression (6, 112). These 
findings suggest that ATRA administration alters methyl group and homocysteine 
metabolism in a manner that is distinct from diabetes and an interaction exists between them. 
Others have shown that vitamin A and its derivatives reduced SAM-dependent synthesis of 
PC and its concentrations in the liver (107, 130); however, in our studies reported here, no 
such interaction was evident with respect to the activity of PEMT and phospholipid 
methylation. 
In summary, we have shown that type 1 diabetes is characterized by an upregulation 
of SAM-dependent phospholipid methylation and is characterized by a state of 
hypohomocysteinemia, due to elevations in folate-independent re-methylation of 
homocysteine. choline is important for PC synthesis and is significant source of methyl 
groups in the liver through its oxidation to betaine. For ZDF rats, Wijekoon et al. (95) 
recently found reduced betaine concentrations in the liver and an increase in the activity of 
BHMT. Moreover, they also found decreased hepatic PC concentrations and attributed this 
to increased oxidation of choline to betaine for BHMT, thereby compromising the 
availability of choline for the CDP-pathway. Furthermore, Igolnikov and Green (79) found 
increased PEMT activity in mice fed a choline deficient diet. Taken together with the 
increased utilization of PC for bile secretion, our research supports the possibility that 
diabetes may result in an increased choline requirement. This not only has implications for 
altered phospholipid methylation in diabetes, but also the subsequent regulation of 
homocysteine homeostasis. This latter implication is important with respect to the 
progression of diabetes, as it has been well documented that both type 1 and type 2 diabetes 
eventually progresses to a state of hyperhomocysteinemia, particularly when diabetic 
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nephropathy is evident (95, 131-136). The temporal and tissue-specific regulation of PEMT 
and homocysteine will be an important area for future research, in large part owing to the 
association of hyperhomocysteinemia with vascular disease and other pathological 
conditions. Likewise, the potential benefit of choline and/or betaine supplementation as a 
viable diabetes intervention strategy needs to be examined. 
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Figure Legends 
FIGURE 3.1. Streptozotocin (STZ)-mediated diabetes rapidly increased the activity of 
hepatic phosphatidylethanolamine N-methyltransferase (PEMT). Rats received an 
intraperitoneal injection of either STZ (60 mg/kg body weight) or vehicle (10 mmol/L citrate 
buffer, pH 4.5) on d 0 and were sacrificed on d 0, 3, 5, or 7. Liver samples were collected 
and PEMT activity was determined as described under "Materials and Methods". Data are 
expressed as mean ~ SEM (n=6). Values with an asterisk indicates that they were 
significantly different from control (d 0) values, P < 0.05. 
FIGURE 3.2. Streptozotocin (STZ)-mediated diabetes increased 
phosphatidylethanolamine N-methyltransferase (PEMT) activity, whereas all-trans- 
retinoic acid (ATRA) administration was without effect. Rats were injected with STZ (60 
mg/kg body weight) or vehicle (10 mmol/L citrate buffer) on d 0 followed by administration 
of ATRA (30 µmol/kg body weight) or vehicle (corn oil) for 5 d. Liver samples were 
collected and PEMT activity was determined as described under "Materials and Methods". 
Data are expressed as mean ~ SEM (n=6). Bars denoted with an asterisk indicates that they 
were significantly different from control values, P < 0.05. 
FIGURE 3.3. Streptozotocin (STZ)-mediated diabetes and all-trans-retinoic acid 
(ATRA) administration decreased plasma total homocysteine concentrations. Rats were 
injected with STZ (60 mg/kg body weight) or vehicle (10 mmol/L citrate buffer) on d 0 
followed by administration of ATRA (30 µmol/kg body weight) or vehicle (corn oil) for 5 d. 
Blood samples were collected via cardiac puncture, centrifuged, and the plasma fraction used 
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for the determination of homocysteine concentrations by HPLC as described under 
"Materials and Methods". Data are expressed as mean ~ SEM (n=6). Bars denoted with an 
asterisk indicates that they were significantly different from control values, P < 0.05. 
FIGURE 3.4. Streptozotocin (STZ)-mediated diabetes and all-trans-retinoic acid 
(ATRA) administration decreased phosphatidylethanolamine (PE) and increased 
phosphatidylcholine (PC) concentrations. Rats were injected with STZ (60 mg/kg body 
weight) or vehicle (10 mmol/L citrate buffer) on d 0 followed by administration of ATRA 
(30 µmol/kg body weight) or vehicle (corn oil) for 5 d. Liver samples were collected and 
phospholipid concentrations were determined as described under "Materials and Methods". 
Data are expressed as mean ~ SEM (n=6). Values denoted with different letters indicates 
that they were significantly different from control values, P < 0.05. The statistical results 
were the same for all three values (PE, PC, PE:PC) within each treatment group. 
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Tables and Figures 
Table 3.1 
Triacylglycerol compositions of rat livers and plasma from the control, diabetic (STZ, 
60 mg/kg body weight), all-trans-retinoic acid supplemented (ATRA, 30 µmol/kg body 
weight), and STZ+ATRA treatment groups 
Values are expressed as mean ~ SEM (n=6). Values within a row with a different letter 
subscript are significantly different, P < 0.05. 
Control STZ ATRA STZ+ATRA 
Triacylglycerols 
Liver (mg/g live) 3.48 ~ 0.51 a 1.92 + 0.18a 8.60 ~ 1. l Ob 2.00 + 0.12a
Plasma (mmol/L) 0.97 + 0.15a 1.91 + 0.66a 1.45 + 0.20a 4.78 + 1.03b 
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CHAPTER 4. CHOLINE AND BETAINE SUPPLEMENTATION DID 
NOT ATTENUr~TE EFFECTS OF DIABETES ON 
PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE1
Abstract 
Phosphatidylcholine (PC) is an essential compound in cell membranes, VLDL, cell 
signaling, and bile secretion. PC synthesis in the liver can be achieved by two different 
pathways, the CDP-choline pathway and the phosphatidylethanolamine N-methyltransferase 
(PEMT) pathway. The CDP-choline pathway synthesizes PC directly from choline, whereas 
PC synthesis by the PEMT pathway is achieved via methylation of 
phosphatidylethanolamine (PE) and is not directly dependent on choline. Betaine-
homocysteine S-methyltransferase (BHMT) utilizes betaine to re-methylate homocysteine to 
methionine. Betaine can be obtained directly from the diet or through oxidation of choline. 
Previously, we have shown PEMT and BHMT activities are elevated in the diabetic state. 
This study was conducted to determine if choline or betaine supplementation would decrease 
PEMT activity as a result of an increased availability of choline for the CDP-choline 
pathway. Twenty-four male Sprague-Dawley rats were randomly assigned to be fed the 
control diet or to be supplemented with 1 %choline or betaine. Following a 10-d period on 
their respective diets, half the rats on the control diet and all of the rats in the supplemented 
groups received a single injection of streptozotocin (STZ, 60 mg/kg body weight). PEMT 
activity was elevated 107-127% in all STZ treatment groups. Supplementation had no effect 
on PEMT activity, whereas GNMT activity and abundance were increased 147% and 234%, 
respectively. CBS protein abundance was elevated in all STZ groups regardless of diet. 
These results suggest PEMT activity is not elevated to account for decreased choline 
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availability to the CDP-choline pathway. It is more likely that PEMT activity is hormonally 
regulated in the diabetic state. 
Introduction 
Choline and betaine are found in a wide variety of food sources. Choline can be 
metabolized to phosphatidylcholine, sphingomeylin, acetylcholine, platelet-activating factor, 
and betaine (16). Phosphatidylcholine (PC)2 is an important phospholipid for cell 
membranes, cell signaling, VLDL, and bile secretion (114). PC can be synthesized by two 
different pathways in the liver. The first of these pathways, which produces about 70% of 
the hepatic PC, is the CDP-choline pathway. Choline is metabolized to PC in a series of 
reactions with the rate limiting step being the conversion of phosphocholine to cytidine 
diphosphocholine (CDP-choline) by the enzyme CTP:phosphocholine cytidylyltransferase 
(CT) (16). This conversion is also the regulated step of PC synthesis by the CDP-choline 
pathway. The other pathway for hepatic synthesis of PC is the methylation of 
phosphatidylethanolamine (PE) to PC by phosphatidylethanolamine N-methyltransferase 
(PEMT) (16). PEMT is not necessary for survival as Pemt ~- knock-out mice on a choline 
sufficient diet survive, but develop hepatic steatosis (137). However, hepatocytes lacking 
PEMT secreted 50% less triacylglycerols in apoB-100-containing VLDL than hepatocytes 
with PEMT, while there was no change in the secretion of PC (127). There was no change in 
apoB-100 secretion in mice fed a choline-deficient diet for 3 or 21 d (138). This evidence 
suggests PC synthesis via PEMT is necessary for normal VLDL secretion and is a possible 
reason why Pemt ~- knock-out mice develop hepatic steatosis regardless of the dietary choline 
intake. 
Previously, we have shown the streptozotocin (STZ)-mediated diabetes in rats 
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increases the activity of hepatic PEMT (see previous chapter). This is significant because 
PEMT is a major consumer of methyl groups in the liver and so has the ability to 
considerably contribute to homocysteine concentrations. Plasma total homocysteine goes 
down with the onset of Type 1 diabetes, but becomes elevated as nephropathy due to diabetes 
progresses (94). Homocysteine concentrations go down with diabetes due to the increased 
re-methylation of homocysteine to methionine by betaine-homocysteine S-methyltransferase 
(BHMT) and the increased transsulfuration of homocysteine to cysteine by cystathionine (3- 
synthase (CBS) (6). The increased activity of BHMT leads to an increased usage of betaine 
in the liver. This may cause a decrease in hepatic betaine concentrations, which has been 
shown in a Type 2 diabetic model (95). Choline has the ability to be oxidized to betaine and 
in fact as much as 60% of choline may be oxidized to betaine in the liver (11). The ability of 
choline to be oxidized raises the possibility that, not only are hepatic betaine concentrations 
diminished in diabetes, but also choline. With less available choline, PC synthesis via the 
CDP-choline pathway would be diminished, making it necessary for the PEMT pathway to 
produce more choline. There has also been evidence that there is increased biliary PC 
secretion in the diabetic state, increasing the need for PC synthesis (126). We investigated 
the effect of choline and betaine supplementation on PEMT activity to determine if in fact 
there is an increased choline or betaine requirement in the diabetic state. 
Materials and Methods 
Chemicals 
Reagents were obtained from the following: S-adenosyl-z-[methyl-3H]methionine, 
PerkinElmer Life and Analytical Sciences (Boston, MA); STZ and SAM, Sigma-Aldrich (St. 
Louis, MO); betaine anhydrous (98%pure), Acros Organics (Belgium). All other chemicals 
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were analytical grade. 
Animals and diets 
All animal experiments were performed in compliance with the Iowa State University 
Laboratory Animal Resources Guidelines. Twenty-four male Sprague-Dawley (Harlan 
Sprague-Dawley, Indianapolis, IN) rats (125-149 g) were housed in plastic cages with a 
twelve-hour light:dark cycle and given food and water ad libitum. All rats were randomly 
assigned to receive one of three diets. Twelve rats were fed the control diet, containing 0.2% 
choline bitartrate, which has been previously described (113), six rats were fed the control 
diet supplemented with choline to the level of 1 %, and six rats were fed the control diet plus 
1% betaine anhydrous. This level of supplementation was chosen because a similar level 
was used in other rodent studies (139, 140). After the rats had been on their respective diets 
for 10 days, 6 of the rats on the control diet and all of the rats on the supplemented diets were 
injected with streptozotocin (STZ; 60 mg/kg body weight). The remaining six rats on the 
control diet were injected with the vehicle (10 mmol/L citrate buffer, pH 4.5). On d 15, rats 
were anesthetized with an intraperitoneal injection of ketamine:xylazine (90:10 mg/kg body 
weight) and blood samples were collected via cardiac puncture in heparinized syringes. 
Samples of whole blood were used to determine blood glucose using a commercial kit 
(Sigma-Aldrich, St. Louis, MO). A cut-off of 20 mmol/L blood glucose was used to 
determine if the rats were diabetic or not. There were two rats in the streptozotocin group on 
control diet and one rat in the streptozotocin group on the 1 %choline diet that did not reach 
this cut-off and were excluded from additional analyses. Additional whole blood samples 
were centrifuged at 4,000 X g for 5 min and the plasma fraction was stored at -70°C until 
analysis. Livers were rapidly removed and aone-gram portion was used for preparation of 
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microsomes; remaining liver samples were snap-frozen in liquid nitrogen and stored at 
-70°C. 
Isolation of liver microsomes 
Approximately 1 g of liver was homogenized with a Polytron-Aggregate apparatus in 
4 volumes of ice-cold 10 mmol/L Tris HCl (pH 7.4) containing 0.25 mol/L sucrose. The 
homogenate was centrifuged at 16,000 X g for 20 min at 4°C followed by centrifugation of 
the supernatant (1-2 mL) at 105,000 X g for 60 min at 4°C. The resulting supernatant was 
discarded and the pellet was resuspended in 400 µL of 0.25 mol/L sucrose. The microsomal 
fraction was stored at -70°C until determination of PEMT activity. For GNMT activity and 
GNMT and CBS abundance, 1 mL of the supernatant from the 16,000 x g centrifugation was 
added to 10 µL of 2-mercaptoethanol and stored at -70°C until the time of analysis. Protein ~-
concentrations of the microsomal fraction and supernatant were determined by the Bradford 
method (119) using a commercial kit (Coomassie Plus, Pierce). 
PEMT activity 
The enzymatic activity of PEMT was determined by measuring the incorporation of 
radiolabeled methyl groups from S-adenosyl-L-[methyl-3H]methionine into phospholipids by 
the method of Duce et al. (120) with modifications. In brief, the reaction mixture contained 
0.1 mmol/L SAM, 2 µCi S-adenosyl-L-[methyl-3H]methionine, 10 mmol/L HEPES, 4 
mmol/L dithiothreitol (DTT), 5 mmol/L MgCl2, and 750 µg protein in a final volume of 550 
µL. Following incubation in a 3 7°C water bath for 10 min, the reaction was terminated by 
pipetting 100 µL of the assay mixture into 2 mL of chloroform:methanol:2 N HCl (6:3:1, 
v:v:v) in duplicate. The chloroform phase was washed three times with 1 mL of 0.5 mol/L 
KC1 in 50% methanol, transferred to a glass scintillation vial, and dried at room temperature. 
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The dried lipid fraction was reconstituted in 5 mL Scintverse~ (Fisher Scientific, Pittsburgh, 
PA) and the radioactivity was determined by liquid scintillation counting. 
GNMT activity 
The enzymatic activity of GNMT was measured based on the method of Cook and 
Wagner (141) with slight modifications (112). The assay was performed in triplicate using 
250 µg protein and a reaction mixture containing the following: 200 mM Tris buffer (pH 
9.0), 2 mM glycine, 5 mM dithiothreitol, and 0.2 mM S-adenosyl-L-[methyl-3H]methionine. 
Following a 30 min incubation period at 25°C, 10% trichloroacetic acid was added to stop 
the reaction and activated charcoal was used to remove the unreacted SAM. Samples were 
centrifuged at 14,000 x g and a 200 µL aliquot of the supernatant was added to 5 mL 
Scintverse°  (Fisher Scientific, Pittsburgh, PA). Radioactivity was determined by liquid 
scintillation counting. 
GNMT and CBS protein abundance 
Three samples from each treatment group were randomly chosen to determine 
abundance of GNMT and CBS proteins using immunoblotting methods described previously 
(112). In brief, a 10-20% gradient SDS-polyacrylamide gel was utilized to separate the 32- 
kDa monomer subunit of GNMT and the 64-kDa subunit of CBS. Proteins were transferred 
to nitrocellulose paper and incubated with a 1:2,500 dilution of the monoclonal GNMT 
antibody (142) overnight at 4°C. The membrane was then incubated with a 1:5,000 dilution 
of a goat anti-mouse horseradish peroxidase secondary antibody for 1 hr at room 
temperature. GNMT protein abundance was detected using chemiluminescence and 
exposure of the membrane to Kodak X-Omat AR film. After detecting GNMT abundance, 
the membrane was stripped using RestoreTM Western Blot Stripping Buffer (Pierce). The 
59 
membrane was incubated with a 1: 80,000 dilution of the polyclonal CBS antibody overnight 
at 4°C. Following incubation with the primary antibody, the membrane was incubated with a 
1:5,000 dilution of a goat anti-rabbit horseradish peroxidase secondary antibody for 1 hr at 
room temperature. CBS protein abundance was detected in the same manner as GNMT 
protein abundance. Band density was determined using SigmaGel software (SPSS, Chicago, 
IL). 
Plasma homocysteine 
Total homocysteine (free and protein-bound) concentrations were determined 
according to a previously described method (123). Briefly, 300 µL of plasma, 30 µL 1 
mmol/L N-acetylcysteine, and 30 µL 10% tributylphosphate in dimethylformamide were 
incubated at 4°C for 30 min. To terminate the reaction, 300 µL of 10% trichloroacetic acid 
and 1 mmol/L EDTA were added and samples were centrifuged at 1,000 X g for 5 min. For 
derivatization, a 100 µL sample of the supernatant was transferred to a tube containing 20 µL 
1.55 mol/L sodium hydroxide, 250 µL borate buffer (0.125 mol/L, pH 9.5), and 100 µL 4- 
fluoro-7-sulfobenzofurazan (1 g/L). Samples were incubated for 60 min at 60°C, filtered, 
and analyzed using HPLC with fluorometric detection. 
Lipid analysis 
Frozen liver samples were thawed and total liver lipids were extracted by the method 
of Folch et al. (124). A portion of the extract was dried and weighed to determine total liver 
lipids. Using plasma from whole blood and Folch lipid extracts of liver, triacylglycerols 
were determined by a spectrophotometer and a commercial kit (Sigma-Aldrich, St. Louis, 
MO). 
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Statistical analysis 
The mean values from each treatment group were compared using one-way ANOVA 
at a significance level of 5%. If there was a significant difference among the means, 
comparisons were accomplished using Fisher's least significant difference procedure. 
Correlation coefficients were determined using Pearson Product Moment. All statistical 
analyses were performed using SigmaStat 3.1 (SPSS, Chicago, IL). 
Results 
PEMT Activity was not attenuated by choline or betaine supplementation. 
PEMT activity was elevated by 107-127% in the STZ groups as compared to the control 
(Figure 4.1). There was no effect of choline or betaine supplementation on PEMT activity in 
the STZ-diabetic rats. 
GNMT activity and abundance were significantly increased with betaine 
supplementation. GNMT activity was increased by 58% and 72% in the STZ groups on the 
control diet and 1 %choline diet, respectively (Figure 4.2). 1 %betaine supplementation in 
the STZ-diabetic rats caused an even greater increase in GNMT activity of 147%. The 
changes in GNMT activity were reflected in an increased protein abundance of GNMT in the 
STZ-diabetic rats supplemented with 1 %choline or 1 %betaine. 
CBS protein abundance was not altered by choline or betaine supplementation. 
CBS protein abundance was increased to 158-193% of the control in all STZ-treatment 
groups (Figure 4.3). However, there was no difference in CBS protein abundance among the 
different dietary groups. 
Plasma total homocysteine was not significantly different among the treatment 
groups. Due to a wide variability of homocysteine concentrations within each treatment 
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group, there was no significant difference in plasma total homocysteine between the groups 
(Figure 4.4). There did appear to be a trend towards increased homocysteine with increased 
supplementation among the diabetic groups. 
Liver lipids were significantly reduced in the diabetic treatment groups. There 
was a decrease in total liver lipids of 14-21 % in all STZ-diabetic groups as compared to the 
control group (Table 4.1). There were no significant differences in plasma triglycerides due 
to large variations within treatment groups and small sample sizes. However, there did 
appear to be a trend towards increased plasma TAG in the STZ-diabetic groups. 
Discussion 
As a maj or consumer of hepatic methyl groups, PEMT can have a significant effect 
on homocysteine concentrations. It is important to keep plasma homocysteine concentrations 
low because elevated homocysteine is an independent risk factor for cardiovascular disease 
(4, 132). Hypohomocysteinemia follows the onset of Type 1 diabetes, with 
hyperhomocysteinemia developing concomitantly with nephropathy as diabetes progresses 
(143). Increased activity of PEMT and GNMT may lead to increased homocysteine levels. 
Therefore, it is important to determine why PEMT activity is upregulated in Type 1 diabetes 
in order to prevent it. 
One possible reason is a lack of choline for PC synthesis via the CDP-choline 
pathway due to increased choline being oxidized to betaine for re-methylation of 
homocysteine. We tested this theory by supplementing rats with 1 %choline or 1 %betaine 
for 10 d prior to the onset of diabetes. PEMT activity remained elevated in streptozotocin-
diabetic rats despite 15 d of choline or betaine supplementation. It is possible that the 
optimal amount of time or supplement was not used. However, it is more likely that PEMT 
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activity is not regulated by choline or betaine concentrations. There have been several papers 
suggesting PEMT activity is regulated by glucagon in a cAMP-dependent manner (72, 75, 
118). PEMT may be hormonally upregulated to account for the increased need for PC 
synthesis due to elevated biliary PC secretion (126). Furthermore, studies have shown cAMP 
analogues inactivate CT by phosphorylation causing its release from the ER and Golgi 
membranes (144). This effectively inhibits PC synthesis via the CDP-choline pathway. This 
may be the mechanism used to coordinate PC synthesis via the CDP-choline pathway and the 
PEMT pathway. 
There has also been evidence that hyperglucagonemia upregulates other enzymes in 
the methyl pathway such as GNMT and CBS (145). Similar to previous results (6), GNMT 
activity was increased with diabetes, but it was further increased with 1 % betaine 
supplementation. GNMT abundance was not significantly elevated in the diabetic group on 
the control diet, but was in the diabetic groups supplemented with 1 % choline or 1 % betaine. 
GNMT is responsible for optimizing the SAM to SAH ratio (36). The increased flux through 
the BHMT pathway elevates the amount of SAM in the hepatic one-carbon pool, which 
would lead to an increased need for GNMT to remove excess SAM. Choline and betaine 
supplementation would further increase the flux through the BHMT pathway and lead to an 
even greater surplus of SAM, so GNMT activity would be further elevated. 
In agreement with previous findings (6), CBS protein abundance is elevated in Type 1 
diabetes regardless of choline or betaine supplementation. One might have expected a 
decrease in CBS with betaine supplementation due to increased re-methylation of 
homocysteine by BHMT. However, as mentioned previously there is evidence to show that 
CBS is transcriptionally regulated by glucagon levels (145). 
63 
Supplementation with betaine is currently being explored to prevent or reverse 
hepatic steatosis (1, 28, 139) and lower plasma total homocysteine levels (1, 30, 146). We 
found a trend towards increased homocysteine levels with betaine supplementation in the 
diabetic state. This suggests further studies would need to be done before betaine 
supplementation can be recommended to diabetics to control their homocysteine levels. 
Moreover, liver lipids were decreased in all diabetic groups regardless of diet. The exact 
cause of nonalcoholic steatohepatitis (NASH) is not known, but one mechanism that has been 
suggested release of cytotoxic free fatty acids from triglycerides that have accumulated in the 
liver (28). Our data suggests, that at least in the early stages of diabetes, triglycerides are not 
accumulating in the liver, and betaine supplementation has no effect on liver lipids in the 
diabetic state. While not all diabetics develop NASH, approximately 75% of people with ~-
NASH in the US have diabetes (90, 91). Once again further studies need to be done before 
betaine supplementation can be safely recommended to diabetics for the prevention of 
NASH. 
In summary, lack of choline for PC synthesis via the CDP-choline pathway does not 
appear to be the reason for the increased activity of hepatic PEMT in a diabetic state. PEMT 
activity may be altered by a change in phosphorylation state due to perturbed hormone levels 
in diabetes. Furthermore, choline and betaine supplementation may actually be detrimental 
in the diabetic state due to the increased supply of SAM leading to increased homocysteine 
production. While betaine supplementation has been useful in lowering homocysteine (1, 30, 
146) and preventing hepatic steatosis (28) in otherwise healthy humans, more research needs 
to be done with diabetes before it can be recommended. 
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Footnotes 
1 This work was funded by the American Diabetes Association 
2The abbreviations used are: apoB-100, apolipoprotein B-100; BHMT, betaine homocysteine 
s-methyltransferase; CBS, cystathionine (3-synthase; CDP, cytidine 5'-diphosphate; CT, 
CTP:phosphocholine cytidylyltransferase; ER, endoplasmic reticulum; GNMT, glycine N-
methyltransferase; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PEMT, 
phosphatidylethanolamine N-methyltransferase; SAH, S-adenosylhomocysteine; SAM, S- 
adenosylmethionine; STZ, streptozotocin; TAG, triacylglycerol; and, VLDL, very low 
density lipoprotein. 
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Figure Legends 
Figure 4.1. Phosphatidylethanolamine N-methyltransferase (PEMT) activity in 
streptozotocin (STZ)-mediated diabetic rats was unaltered by choline or betaine 
supplementation. Rats were fed a diet consisting of 0.2% choline bitartrate, 1 %choline 
bitartrate, or 1 %betaine anhydrous for 10 d. On d 10 rats were injected with streptozotocin 
(STZ, 60 mg/kg body weight) or vehicle (10 mmol/L citrate buffer, pH 4.5). On d 15 liver 
samples were collected and PEMT activity was determined as described under "Materials 
and Methods". Data are expressed as mean ~ SEM (n=4, 5, or 6). Values with an asterisk 
indicates that they were significantly different from control values, P < 0.05. 
Figure 4.2. Glycine N-methyltransferase (GNMT) activity and abundance were 
increased in streptozotocin (STZ)-mediated diabetic rats and were further increased by 
1 %betaine supplementation. Rats were fed a diet consisting of 0.2% choline bitartrate, 
1 %choline bitartrate, or 1 %betaine anhydrous for 10 d. On d 10 rats were injected with 
streptozotocin (STZ, 60 mg/kg body weight) or vehicle (10 mmol/L citrate buffer, pH 4.5). 
On d 1 S liver samples were collected and GNMT activity and protein abundance were 
determined as described under "Materials and Methods". Data are expressed as mean ~ SEM 
(n=3, 4, 5, or 6). Values denoted with different letters indicates that they were significantly 
different from control values, P < 0.05. 
Figure 4.3. Cystathionine ~3-synthase (CBS) protein abundance was increased by 
streptozotocin (STZ)-mediated diabetes and was unaffected by choline and betaine 
supplementation. Rats were fed a diet consisting of 0.2% choline bitartrate, 1 %choline 
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bitartrate, or 1 %betaine anhydrous for 10 d. On d 10 rats were injected with streptozotocin 
(STZ, 60 mg/kg body weight) or vehicle (10 mmol/L citrate buffer, pH 4.5). On d 15 liver 
samples were collected and CBS protein abundance was determined as described under 
"Materials and Methods". Data are expressed as mean ~ SEM (n=3). Bars with an asterisk 
indicates that they were significantly different from control values, P < 0.05. 
Figure 4.4. Plasma total homocysteine was not significantly different among any 
treatment group. Rats were fed a diet consisting of 0.2% choline bitartrate, 1 %choline 
bitartrate, or 1 %betaine anhydrous for 10 d. On d 10 rats were injected with streptozotocin 
(STZ, 60 mg/kg body weight) or vehicle (10 mmol/L citrate buffer, pH 4.5). On d 15, blood 
samples were collected via cardiac puncture, centrifuged, and the plasma fraction used for 
the determination of homocysteine concentrations by HPLC as described under "Materials 
and Methods". Data are expressed as mean ~ SEM (n=4, 5, or 6). 
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Tables and Figures 
Table 4.1 
Liver lipid and plasma triacylglycerol (TAG) concentrations from control and diabetic 
(STZ, 60 mg/kg body weight) on three different diets; 0.2% choline, 1% choline, and 
1% betaine 
Values are expressed as mean ~ SEM (n=4, 5, or 6). Values within a row with a different 
letter subscript are significantly different, P < 0.05. 
2° h 
0.2% Choline 
0. /o C oline + 
STZ 
1%Choline 
+ STZ 
1% Betaine 
+ STZ 
Liver Lipids 
(mg/g liver) 
Plasma TAG 
(mmol/L) 
38.25 ~ 1.28a 32.78 ~ 0.23b 30.13 ~ 0.76b 31.89 + 1.46b
0.82 + 0.12 2.03 + 0.86 1.77 + 0.62 2.61 + 1.06 
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Figure 4.1 
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Figure 4.2 
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Figure 4.3 
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Figure 4.4 
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CHAPTER 5. GENERAL CONCLUSIONS 
Phosphatidylcholine (PC) is essential for many actions in the body including cell 
membrane integrity, bile, VLDL secretion, and cell signaling. There are two major pathways 
to synthesize PC in the body; the CDP-choline pathway and the PEMT pathway. The CDP-
choline pathway requires choline, whereas the PEMT pathway requires methyl groups. 
Under normal conditions, PEMT synthesizes approximately 30% of the hepatic PC (7-9). 
This makes PEMT a key enzyme in the methyl group metabolism pathway and is considered 
by some to be an important regulator of homocysteine (10, 43). 
There are several factors that modulate hepatic methyl group metabolism. In the 
beginning of this thesis we focused on diabetes and administration of retinoids. While 
retinoids affect other enzymes involved in methyl group metabolism, it appeared they had no 
effect on PEMT activity. However, streptozotocin-diabetes consistently and rapidly caused a 
2-fold induction of PEMT activity. There is evidence that diabetics have increase biliary PC 
secretion, which would require increased PC synthesis (126). Also, PC synthesis, 
particularly via phospholipid methylation, is important in maintaining VLDL secretion (77, 
127, 13 7, 13 8, 147) to prevent fatty liver. we did not directly investigate the affects of 
diabetes on the CDP-choline pathway, so at this time it is unclear if PEMT activity is 
increased to meet an increased demand for PC synthesis or if it is in response to decreased 
PC synthesis by the CDP-choline pathway. 
To try to elucidate if the increase in PEMT activity seen with diabetes is in response 
to a decrease in PC synthesis by the CDP-choline pathway, we tried supplementing diabetic 
rats with choline or betaine. It was reasoned that the increase in BHMT activity seen with 
diabetes may be resulting in an increased requirement for choline or betaine. It was found 
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that choline and betaine supplementation had no effect on PEMT activity in the diabetic 
state. However, betaine supplementation did further increase the activity of another methyl 
transferase, GNMT, and it seemed to attenuate the decrease in plasma total homocysteine 
typically seen with the onset of diabetes. Betaine supplementation is currently used to lower 
plasma homocysteine levels in individuals with hyperhomocysteinemia and is being studied 
to prevent or reverse hepatic steatosis (l, 28, 30, 139, 146, 148-150). These two diseases are 
considered to be major complications of diabetes. It appears that the preliminary work from 
our study shows that betaine supplementation may not be an effective treatment in diabetics 
for hyperhomocysteinemia and hepatic steatosis and may in fact be detrimental to their 
health. 
Another conclusion that can be drawn from this final study is that it is not a lack of 
choline for the CDP-choline pathway that is driving the increase in PEMT activity seen with 
diabetes. This further supports other studies suggesting the PEMT activity is hormonally 
regulated by glucagon and that elevated levels of glucagon typically seen with diabetes is the 
cause for increased PEMT activity (75, 118, 145). They also tested the affect of cAMP 
analogues and found similar increases in PEMT activity as those seen with glucagon 
treatment (75). This led them to conclude there is either increased or decreased 
phosphorylation of the enzyme in the diabetic state leading to its increased activity. This is 
an avenue that needs to be explored further. If it is the elevated glucagon that is causing the 
alterations, then it may be necessary in the future for diabetics to monitor their glucagon 
levels as well as their insulin levels. 
There is much work that needs to be done in this area to determine the mechanism for 
how diabetes alters phospholipid methylation, how this affects PC synthesis, and what 
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overall consequences does this have on the body. This work will require primary 
hepatocytes cell cultures to determine the direct signals causing increased PEMT activity. It 
will probably also be necessary to look at PC synthesized by the CDP-choline pathway in the 
diabetic state. And finally, it will be necessary to determine how this affects bile secretion, 
VLDL secretion, cell membrane integrity, and homocysteine levels. Also, betaine 
supplementation in diabetic rats should be studied for a longer time period and at different 
levels to determine if there are any detrimental affects of supplementation. Until longer term 
studies have been done, it should not be recommended that diabetics supplement their diets 
to lower homocysteine or treat hepatic steatosis. It will also be necessary to determine if 
insulin injections to diabetic rats can reverse some of the alterations found in order to help 
translate these findings to human subjects. Once the consequences of diabetes on 
phospholipid synthesis and usage are better understood, we can then move forward with 
better treatments. 
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APPENDIX: EFFECTS OF DIABETES AND FOLATE STATUS ON 
PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE AND 
GUANIDINOACETATE N-METHYLTRANSFERASE1
Introduction 
Folate status is highly important in regulation of methyl group metabolism. Folate 
and betaine are responsible for donating one-carbon units to homocysteine in order to 
regenerate methionine. Folate deficiency can lead to decreased levels of S- 
adenosylmethionine (SAM) and increased levels of S-adenosylhomocysteine (SAH), causing 
inhibition of methyltransferases. Type 1 diabetes has also been shown to alter the activities 
of many methyltransferases including GNMT and BHMT (6). This study was conducted to 
determine how folate status combined with diabetes affect the activities of 
phosphatidylethanolamine N-methyltransferase (PEMT) and guanidinoacetate N- 
methyltransferase (GAMY). 
Materials and Methods 
Animals 
All experiments involving animals were approved by and conducted in accordance 
with the Iowa State University Laboratory Animal Resources guidelines. Thirty-six male 
Sprague-Dawley (Harlan Sprague-Dawley, Indianapolis, IN) rats (50-74 g) were housed in 
separate cages with a 12-h light: dark cycle and were allowed access to food and water ad 
libitum. Rats were randomly assigned to treatment groups and fed an amino-acid defined 
diet (Harlan Teklad, Madison, WI) containing either 0 (folate-deficient, FD), 2 (folate- 
adequate, F), or 8 ppm folate (folate-supplemented, FS). After 30 d, half of the rats in each 
dietary folate group received a single intraperitoneal injection of streptozotocin (STZ, 60 
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mg/kg body weight) or vehicle (10 mM citrate buffer, pH 4.5). On day 35, rate► were 
anesthetized with ketamine: xylazine (90: 10 mg/kg body weight). The liver was snap-frozen 
in liquid nitrogen and stored at -70°C until determination of PEMT and GAMT' activities. 
Determination of PEMT and GAMT activity 
Approximately 1 g of frozen liver was homogenized in 4 volumes of icf~-cold 10 mM 
Tris HC1(pH 7.4) containing 0.25 M sucrose. The homogenate was centrifuged at 16,000 x 
g for 20 min at 4°C and 1-2 mL of the resulting supernatant was centrifuged at 105,000 x g 
for 60 min at 4°C. The supernatant was discarded and the microsomal pellet was 
resuspended in 400 µl of 0.25 M sucrose. The microsomal fraction was stored at -70°C until 
analysis. Total soluble protein concentrations were determined by the method of Bradford 
(119). PEMT activity was determined by measuring the incorporation of radiol.abeled methyl 
groups from S-adenosyl-L- [methyl-3H]methionine into phospholipids by the mE;thod of Duce 
et al. (120) with modifications. Briefly, the reaction mixture contained 10 mM HEPES (pH 
7.3), 4 mM dithiothreitol, 5 mM MgCl2, 0.1 mM SAM, 2 µCi S-adenosyl-L-[mf~thyl-
3H]methionine, and 750 µg protein in a final volume of 550 µL. The reaction v~~as initiated 
by adding 75 µL microsomal protein (10 µg/µL) to the assay mixture and incub~~.ted in a 37°C 
water bath for 10 min. The reaction was terminated by pipeting 100 µL of the assay mixture 
into 2 mL chloroform: methanol: 2 N HCl (6:3:1, v:v:v) in duplicate. The chloroform phase 
was washed three times with 1 mL 0.5 M KCl in 50% methanol, transferred to ~~ glass 
scintillation vial, and allowed to dry at room temperature. The lipid fraction wa.s 
reconstituted in 5 mL Scintverse°  (Fisher Scientific, Pittsburgh, PA) scintillation fluid and 
the radioactivity was determined by liquid scintillation counting. GAMT activi~~y was 
analyzed using the method of Xue and Snoswell (98) with modifications. Brief7.y, 500 µg 
~~ 
protein samples were incubated for 20 min at 37°C in a 100 µL reaction volume containing 
50 mM Tris-HCl (pH 7.5), S mM 2-mercaptoethanol, 2 mM guanidoacetate, acid 0.1 µCi S- 
adenosyl-L-[methyl-3H]methionine. The reaction was terminated by the additi~~n of 100 µL 
of 10% trichloroacetic acid and buffered by the addition of 400 µL 0.2 M Tris. Reaction 
samples were applied to a 1 x 3 cm column containing Bio-Rad AG-50-X4 resin (NH4 form, 
50-100 mesh) and eluted with three 1 mL volumes of deionized H2O directly into 
scintillation vials for liquid scintillation counting. 
Results 
PEMT activity was increased with diabetes, but folate status was without effect. 
Phosphatidylethanolamine N-methyltransferase (PEMT) activity was increased by 87-118% 
in all STZ treatment groups versus their controls on the same diets (Table A.1). There were 
no differences among the diet groups in PEMT activity. 
GAMT was decreased with diabetes. In all STZ treatment groups, GAMT activity 
was significantly reduced 40-59% versus their respective controls (Table A.1). The folate- 
sufficient group showed a modestly increased activity of GAMT as compared to the folate- 
deficient and the folate-supplemented groups. 
Discussion 
The increase in PEMT activity in the STZ-diabetic groups was consistent to what was 
shown in our previous studies. The lack of effect by folate-status was also con~;istent with 
the results seen with choline and betaine supplementation. This is simply further evidence 
that the increase in PEMT activity does not seem to be substrate, but more likely hormonally 
regulated. 
~g 
GAMT activity in diabetes may be the result of inhibition by elevated levels of SAH. 
Another possibility is SAM is preferentially shuttled to PEMT to synthesize more PC leaving 
less SAM for GAMT and consequently a decrease in activity. Another possibility is GAMT 
is hormonally regulated. Increased levels of glucagon in the diabetic state is a signal the 
body is in starvation mode. GAMT activity and possibly expression may be decreased to 
conserve methyl groups for more important reactions such as PC synthesis. This could mean 
diabetics have decreased creative production. 
Folate-deficiency and folate-supplementation could lead to less than optimal levels of 
SAM and SAH. GAMT activity in the folate-sufficient non-diabetic group may have been 
increased due an optimized ratio of SAM:SAH. 
In summary, PEMT activity in this study mirrored the results of other studies and 
provided more evidence that PEMT activity is probably not upregulated in diabetes due to a 
change in the size of the hepatic one-carbon pool. The decrease in GAMT activity maybe 
partially responsible for the increase in GNMT activity seen in other studies. With the 
decrease in GAMT activity in the diabetic state, it could be a concern that diabetics are not 
able to synthesize enough creative. Creative is an essential compound for muscle function, 
especially during exercise. Creative supplementation may be necessary in the diabetic state. 
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Footnotes 
1 This study was done on rat liver samples obtained from a study done by Kristin Nieman 
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Tables and Figures 
Table A.1 
Hepatic activity of phosphatidylethanolamine N-methyltransferase (PEMT) and 
guanidinoacetate N-methyltransferase (GAMY) in rats treated with streptozotocin 
(STZ) and fed either 0 (FD), 2 (F), or 8 (FS) ppm dietary folate 
Values are expressed as mean ~ S.E. (n = 6). Values within a column with different letter 
superscript are significantly different, p < 0.05. 
PEMT GAMY 
Bq/min•mg protein pmol/min•mg protein 
FD 26.1 ~ l.l a 0.30 ± 0.02a
FD +STZ 50.1 ± 10.3b 0.15 ± 0.03b
F 28.3 ± 2.Oa 0.44 ± 0.04 
F+STZ 52.8±5.8b 0.18±O.OSb
FS 28.4±2.4a 0.30±O.Ol a
FS+STZ 62.0±5.6b 0.18±0.02b 
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